Published in final edited form as:

Front Biosci (Landmark Ed). ; 22: 1221–1246.

Racial Disparity in Metabolic Regulation Of Cancer

Kuldeep S. Attri¹, Divya Murthy¹, and Pankaj K. Singh^{1,2,3,4,*}

¹Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska, 68198, USA

²Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska, 68198, USA

³Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska, 68198, USA

⁴Department of Genetics, Cell Biology, and Anatomy, University of Nebraska Medical Center, Omaha, Nebraska, 68198, USA

Abstract

Genetic mutations and metabolic reprogramming are two key hallmarks of cancer, required for proliferation, invasion, and metastasis of the disease. While genetic mutations, whether inherited or acquired, are critical for the initiation of tumor development, metabolic reprogramming is an effector mechanism imperative for adaptational transition during the progression of cancer. Recent findings in the literature emphasize the significance of molecular cross-talk between these two cellular processes in regulating signaling and differentiation of cancer cells. Genome-wide sequencing analyses of cancer genomes have highlighted the association of various gene mutations in predicting cancer risk and survival. Oncogenic mutational frequency is heterogeneously distributed among various cancer types in different populations, resulting in varying susceptibility to cancer risk. In this review, we explore and discuss the role of genetic mutations in metabolic enzymes and metabolic oncoregulators to stratify cancer risk in people from different racial backgrounds.

Introduction

The underlying genetic diversity among different human populations that stratifies genomes in various ethnic groups can also manifest resistance or susceptibility to complex polygenic diseases. The skewed distribution of measures of disease frequency such as incidence, prevalence, and mortality, confers differential disease susceptibility risk in these ethnic populations (1). In the post-genomic era, genome-wide meta-analysis of human genome sequences and genome-wide association data sets have led to the identification of multiple disease susceptibility loci associated with an increased risk of complex diseases like type-2

*Correspondence: Pankaj K. Singh, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, 985950 Nebraska Medical Center, Omaha, NE 68198-5950. pankaj.singh@unmc.edu, (Phone) 402.559.2726, FAX: 402-559-2813.

Competing Interests: The authors have declared that no competing interests exist.

diabetes, obesity, Crohn's disease, allergies, and cancer across various ethnic populations (2, 3). These trans-ethnic, genome-wide studies have enhanced understanding of the complex and heterogeneous genetic architecture of diseases, including cancer.

Cancer is a complex disease of multicellular origin, characterized by rapid, unregulated proliferation of cells that invade normal tissues and may metastasize to distant organs (4). Although various cancer pathologies are differentiated based on the site of origin, their risk factors differ based on the ethnic background of those who contract the disease (5). Cancer etiopathogenesis is an outcome of the complex interplay between genetic mutations, epigenetic alterations, and environmental risk factors (6). Genetic alterations in cancer cells are of paramount significance since they dictate the onset and progression of the disease (7). Cancer mutations are acquired and somatic, fixed by natural selection and evolution. Further, they may be inherited in varying frequencies in different populations (5). Recent genetic studies and quantitative population genetic analyses suggest genetic diversity in ethnic populations as a classifier for cancer risk that is population-specific and has shared risk mutations in different populations (8).

Cellular metabolic reprogramming, a key hallmark of cancer, is critical for the survival, progression, and malignant transformation of cancer cells and occurs under an altered micro-environmental state. Metabolic rewiring in tumors benefits host cells by enhancing macromolecular biosynthesis, regulation of redox balance, and rapid ATP generation to meet the requirements of rapidly dividing cells (9). Although the Warburg effect is a key metabolic adaptation known to exist in cancer cells, recent studies indicate metabolic symbiosis, glutamine addiction, and a reverse Warburg effect as newly understood, associated metabolic features (10-12). Mutations in these oncogenic signaling pathways are known to cause differential activation of downstream signaling cascades that further translates to altered metabolic regulations (13). Therefore, in this review, we explore whether genetic mutations in metabolic enzymes or metabolites themselves serve as discriminatory criteria for racial stratification.

Racial Disparity in Incidence, Mortality and Risk Factors in Cancer

Cancer is a complex group of diseases that consist of anatomically distinct pathophysiologies, and that differ in their genesis and manifestation (14). Although cancer is the leading cause of mortalities worldwide, notable differences are observed in disease incidence, prevalence, and mortality rates depending on the ethnic or racial backgrounds of patients (15). In this review, we focus on lung, breast, colorectal, and pancreatic cancer, since these accounts for the majority of cancer incidences and related mortalities. Recent data from the National Cancer Institute on these four most lethal cancers demonstrate prominent differences in incidence and mortality rates among different racial populations. African-Americans, for example, have relatively higher age-adjusted incidence rates for all four cancer types than Caucasians based on combined data for both sexes. The same trend is reflected in mortality rates, indicating late diagnosis and absence of effective therapeutic modalities, for reasons discussed below (Figure 1). The second-highest mortality rates are found among Caucasians, followed by the other three racial populations (15). Nevertheless, in a study conducted on breast cancer over a period of three decades, it was surprising to see

a 40 percent higher mortality rate in females of African-American descent than Caucasian, despite having low overall incidence rates (16). It was also interesting to note that non-Hispanic populations overall showed significantly higher incidence and mortality rates in comparison to Hispanic populations (15).

Socioeconomic status, obesity, basal metabolic index (BMI), smoking, type-2 diabetes, exposure to sunlight and carcinogens, dietary factors such as vitamin intake and nutrient density of foods consumed, and family history are major predictors of cancer risk in all races (17-20). A disproportionately high incidence and mortality rate in African-Americans can be attributed to their genetic architecture, specific environmental influences, or risk factors associated with lifestyle habits (21). Also of note is that males from all five racial populations are at higher risk for lung, colorectal, and pancreatic cancer than are females, as reflected in epidemiological trends. Lung cancer is the leading cause of cancer-related deaths in the United States, and the majority of those deaths are associated with cigarette smoking (22). Based on smoking patterns, African-Americans and Native Hawaiians are more susceptible to lung cancer (23). In females, breast cancer is the second leading cause of cancer-related deaths; however, the severity of the disease is directly correlated with a lack of expression of oncogenic receptors. Triple-negative breast cancers are aggressive tumors with poor prognostic potential, and these also show very high incidences among African-American women (24).

Another example of a notable racial disparity is found in colorectal cancer, where African-American patients also present with skewed incidence and mortality rates compared to the U.S. Caucasian population (25). Colorectal cancer, apart from being the third leading cause of cancer-related deaths, demonstrates remarkable stage-dependant physiological and cellular changes during disease progression (26). Vitamin D deficiency which is widely prevalent in African-American populations is associated with increased risk of diabetes and colorectal cancer (25). Type-2 diabetes mellitus and obesity are other risk factors associated with the difference in the racial stratification of colorectal cancer (27, 28). Pancreatic cancer, one of the leading causes of cancer mortalities in developed countries, has a low survival rate which is primarily attributed to the sudden onset of disease, rapid metastatic rate, and limited therapeutic interventions (29). A 32% higher pancreatic cancer death rate is recorded in African-Americans compared to Caucasians from the United States. The majority of racial disparity in pancreatic cancer patients is accounted for by cigarette smoking, long-term diabetes mellitus, and family history of pancreatic cancer (in females, alcohol consumption and high BMI are additional risk factors) (30-32). While some differences in the incidence of cancer related to race could be attributed to various risk factors, a differential distribution of natural variations in ethnic and racial populations can account for unexplained inequalities. Therefore, we here focus on a population-based stratification of cancer risk based on genetic alterations in metabolic genes and regulators.

Metabolic Reprogramming in Cancer

Tumor cells are rapidly proliferating cells that demand different metabolic requirements to support their unusually high rates of cell growth and proliferation. To meet these challenges, the tumor cells exhibit active metabolic reprogramming by enhancing the glycolytic flux to

lactate in the presence of oxygen (Figure 2). This phenomenon, known as the “Warburg effect,” or “aerobic glycolysis,” is firmly established as a hallmark of cancer where ATP is preferentially generated through aerobic glycolysis instead of oxidative phosphorylation (33). Such metabolic transformation results in the rapid yet inefficient production of ATP per unit of glucose consumed and therefore, impose an atypically high rate of glucose uptake by tumor cells to convene the enhanced anabolic requirements (34).

The cellular uptake of glucose is mediated by glucose transporters (GLUTs) (35). Subsequent to the uptake, the glucose undergoes a series of metabolic reactions to produce glycolytic intermediates which are channelized to secondary metabolic pathways resulting in the generation of macromolecules such as lipids, nucleotides, amino acids and reducing equivalents such as NADPH indispensable for tumor cell survival and progression (36, 37). In glycolysis, glucose is catalyzed by hexokinases (HK2) to produce glucose-6-phosphate which is sequentially acted upon by glucose-6-phosphate isomerase (GPI) and phosphofructokinase1 (PFK1) to produce fructose-1,6-bisphosphate. Fructose-1,6-bisphosphate is converted to glyceraldehyde-3-phosphate and dihydroxyacetonephosphate, which is further shunted to synthesize triacylglycerols and phospholipids, the precursors for cell membrane (38). The glucose-6-phosphate can also be redirected to the oxidative arm of pentose phosphate pathway (PPP) to generate NADPH, which is critical for the maintenance of redox status in tumor cells. Meanwhile, the non-oxidative arm of PPP is involved in the synthesis of ribose-5-phosphate, required for *de novo* synthesis of nucleotides within the cell (39).

The high glycolytic flux in cancer cells is maintained in a multipronged manner. Key regulatory enzymes such as phosphofructokinase-2 (PFK-2), lactate dehydrogenase (LDH) and pyruvate kinase (PK) play a critical role in maintaining the increased glycolytic flux in cancer cells by regulating the levels of fructose-2,6-bisphosphate, NAD^+/NADH ratio, and pyruvate respectively (40-42). Approximately 90% of the pyruvate generated from glucose is channelized to form lactate by LDH-A (33). The lactate produced is readily secreted into the extracellular environment by monocarboxylate transporters (MCTs) rather than being completely oxidized. LDH-A catalyzes pyruvate to lactate conversion to recover NAD^+ required for maintaining glycolysis (41). The constitutively activated uptake and metabolism of glucose in cancer cells is accompanied by major metabolic reprogramming, thus leading to the production of a vast repertoire of cellular ATP that even supersedes the production rate from oxidative phosphorylation (43).

Around 10% of the pyruvate generated from aerobic glycolysis enters the tricarboxylic acid cycle (TCA). However, the pyruvate is extruded from the TCA cycle as diverse metabolites, which are utilized for various biosynthetic processes. Pyruvate is catalyzed by pyruvate dehydrogenase (PDH) to form acetyl-CoA which condenses with oxaloacetate to form citrate (44). The citrate formed is transported from the mitochondria to the cytosol where it is converted back to acetyl-CoA by ATP citrate lyase (ACL). ACL has been demonstrated to be critical for tumor cell proliferation and glucose-dependent lipid biosynthesis (45).

Depletion of TCA cycle intermediates has been shown to alter mitochondrial integrity. The utilization of citrate for lipid synthesis results in depletion of oxaloacetic acid (OAA) which

accepts acetyl-CoA to maintain the levels of TCA cycle metabolites (46). This is accomplished by the stepwise oxidation of glutamine in proliferating cells, another major substrate on which the cancer cells have a metabolic dependency. Glutamine uptake in cancer cells is carried out by the glutamine transporters SLC5A1 and SLC7A1 (47, 48). The glutamine acquired by the cancer cells is transformed into biomass, 60% of which is converted to alanine that is further secreted as cellular waste. Recent studies have established that malignant transformation results in the conversion of glutamine to lactate by glutaminolysis, which utilizes the cytosolic form of malic enzyme 1 (49). This process of partial oxidation provides cells with NADPH for the reductive reactions of fatty acid and nucleotide biosynthesis. Glutamine participates in various anapleurotic processes as well. Glutamine is acted upon by glutaminase to produce glutamate, which is converted to α -ketoglutarate (α -KG) and enters the TCA cycle. The condensation of carbon molecules from glucose-derived acetyl-CoA and glutamine-derived OAA permits the production of fatty acids (50). A recent study has also shown the utilization of isocitrate dehydrogenase-1 (IDH1)-dependent pathway-mediated reductive metabolism of α -KG to synthesize acetyl-CoA for *de novo* lipogenesis under hypoxia (51). Reversal of major canonical reactions of the TCA cycle using glutamine as a precursor leads to the generation of TCA cycle intermediates during dysfunctional mitochondrial metabolism (52). The reprogramming of glutamine metabolism is regulated by KRAS in pancreatic cancer (53). This process of anaplerosis provides the carbon input such as OAA required for the TCA cycle to function as a biosynthetic ‘hub’ wherein the mitochondria are transformed into apparatuses to sustain rapid cell division (54, 55). In addition to its anaplerotic function, glutamine plays a critical role in the maintenance of cellular redox homeostasis. Glutamate derived from glutamine is catalyzed by the enzyme glutathione cysteine ligase to form glutathione (GSH). This reduced form of GSH is a major antioxidant found in mammalian cells that maintain the cellular redox state of all sub-cellular compartments (56).

Mutational Control of Metabolic Regulations

Enzymatic Gene Mutations as Mediators of Metabolic Rewiring

Genetic polymorphism in metabolic genes is tightly associated with altered metabolic profiles resulting in diverse clinical outcomes during cancer pathogenesis (Figure 2). Single nucleotide polymorphisms (SNPs) identified in *Glucokinase* (GK IVS1+9652C→T) and *HK2* N692N homozygous variants are associated with reduced overall survival (OS) in 154 pancreatic adenocarcinoma patients (57). In addition, genetic polymorphism in the *GLUT1* (2841A→T) exhibited significant correlation with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose-uptake in the squamous cell type of non-small cell lung cancer (NSCLC) (58). Of interest, many of the mitochondrial genes harbor mutations that can directly contribute to carcinogenesis. Recent studies have indicated genetic defects in many of the TCA cycle enzymes that include isocitrate dehydrogenase (IDH2), succinate dehydrogenase (SDHA and SDHC), and fumarate hydratase (FH) (59-62). Genetic variations in metabolic oncoregulators such as *SDH*, *FH*, and *IDH*, are associated with prognosis of patients with NSCLC. Genetic mutations in *SDH* and *FH* results in activation of HIF-1 α -mediated glucose utilization (63). Hypoxia-inducible factor-1 α (HIF-1 α) is a central transcription factor that controls major regulatory nodes of the glycolytic pathway leading to enhanced

glycolysis. It is reported that mutations in *SDH* and *FH* results in the accumulation of succinate and fumarate, that may further inhibit the prolyl hydroxylases (PHDs), a class of α -ketoglutarate-dependent enzymes, known to hydroxylate HIF-1 α (64). Hydroxylation of HIF-1 α leads to its degradation by the von Hippel-Lindau-mediated ubiquitination pathways. Thus, germline mutations in *SDH* and *FH* can mark the stabilization of HIF-1 α during carcinogenesis (65). IDHs have been extensively studied in human glioblastoma multiforme, acute myeloid leukemia, and chondrosarcoma. IDH2 catalyzes the conversion of isocitrate to α -KG. Genetic analysis has revealed the IDHs to harbor point mutations that impart new enzymatic activity wherein α -KG is converted to 2-hydroxyglutarate (2-HG), an oncometabolite. In addition to the productions of 2-HG, mutant IDH also results in the reduction of α -KG and thus leads to stabilization of HIF-1 α with a concomitant upregulation of glycolysis (66). In two independent studies performed in NSCLC and colorectal cancer (CRC), three SNPs identified in *MCT1* and *MCT2* genes were associated with clinical outcomes in patients that could be utilized as predictors of response to adjuvant chemotherapy (67, 68). SNPs are also identified in the lipid biosynthetic pathways of the cancer cell as well. Moreover, two other SNPs found in *ACLY* gene are associated with high risk of death in colorectal cancer patients (69). In a recently conducted genome-wide association study, two SNPs in the fatty acid desaturase 1 (*FADS1*) and *FADS2* genes, involved in polyunsaturated fatty acid metabolism, were found to have a strong correlation with their expression in colon tumor tissue as compared to normal tissue. Importantly, arachidonic acid, the product of *FADS2*, is a precursor of prostaglandinE2 that modulates cyclooxygenase activity during colorectal cancer pathogenesis (70). Together these findings, advocate the possibility of exploiting genetic variations in metabolic genes as prognostic markers to determine cancer risk.

Oncogene and Tumor Suppressor-directed Metabolic Rewiring

Metabolic pathways functional in proliferating tumor cells are distinctly regulated by multiple intracellular signaling cascades. These are altered by mutations in known oncogenes and tumor suppressor genes. Such regulatory mutations result in the re-engineering of the entire metabolic machinery to promote survival and growth (Figure 3) (13), but the proliferation of cells is highly dependent on the rate of uptake of nutrients from the microenvironment, a phenomenon dependent on growth factors. The acquisition of genetic mutations in oncogenes leads to altered receptor-initiated signaling pathways in cancer cells, which can result in an increased uptake of nutrients, such as glucose, to compensate for the increased bioenergetic requirements of cancer cells (71).

Mutations in *KRAS*, *p53*, *Myc*, *BRCA1*, or *BRAF* have been extensively studied and have been implicated as orchestrators of metabolic reprogramming in multiple cancers. Oncogenic mutations in *KRAS* and *BRAF* have been shown to drive the EGFR pathway, a signaling cascade critical for promoting tumor proliferation and survival (72, 73). In a recent study in colorectal cancer, mutations in *KRAS* and *BRAF* were shown to increase the expression of the glucose transporter, GLUT1 (74). Activating *KRAS* point mutations are associated with single-point mutations in exon 12, 13, or 61 and are most prevalent in pancreatic cancer (61%), colon cancer (33%), and lung cancers (17%) (75). Lung cancer cells homozygous for the *KRAS*-activating mutation (*Kras*^{G12D}/*Kras*^{G12D}) exhibit a

glycolytic switch wherein the glucose-derived metabolites are shunted into the TCA cycle and glutathione biosynthesis, which assist in enhanced glutathione-mediated detoxification (76).

BRAF gene mutations were identified in varying frequency in 43 different cancer cell lines including 20 of 34 (59%) melanomas, 7 of 40 (18%) colorectal cancers, 4 of 38 (11%) gliomas, 4 of 131 (3%) lung cancers, 5 of 59 (9%) sarcomas, 1 of 26 (4%) ovarian carcinomas, 1 of 45 (2%) breast cancers, and 1 of 7 (14%) liver cancers (77). The *BRAF* V600E mutation is prevalent in melanoma cells, colorectal, and thyroid cancer cells where point mutation leads to a reduction in the expression of TCA cycle enzymes and mitochondrial oxidative phosphorylation (78). Also, the *BRAF* gene mutations were identified in 1% to 3% of all NSCLC samples (79).

The “transcription factor triad,” p53, c-Myc and HIF-1 α , actively orchestrates the energy metabolism of cancer cells (80). p53 is a critical and well-studied tumor suppressor protein involved in the regulation of cell cycle, apoptosis, and cell growth and development. Both p16 (Ink4a) and p19(Arf)-p53 pathways have been shown to constrain the progression of pancreatic adenocarcinomas in mouse (81). p53 not only responds to metabolic changes but influences metabolic processes by controlling various regulatory nodes. A variety of metabolic enzymes are downstream targets of p53. The commonly regulated glucose metabolizing enzymes include the glucose transporters GLUT1, GLUT4, and FBPase, which promote the degradation of fructose-2,6-bisphosphate (F-2,6-BP) (82). In cancer cells, reduction in F-2,6-BP enhances the formation of fructose-6-phosphate, which is converted to metabolic intermediates channelized to PPP (83). In different cancers, inactivation of the p53 tumor suppressor is a common phenomenon, with a mutation rate ranging from 38-50% in ovarian, colorectal, esophageal, lung, and larynx cancers to around 5% in primary leukemia, malignant melanoma, and cervical cancer (84-86). Such oncogenetic changes encompass amplifications, mutations, and gene deletions, giving rise to a mutated yet stable p53 protein that loses tumor-suppressive functions but gains additional oncogenic roles. Such mutations in tumor suppressor genes endow cells with growth and survival advantages (87).

The amplification of *c-Myc* proto-oncogene is frequently observed in different tumor forms mediated through multiple mechanisms; initial studies indicate the major role of c-Myc in self-renewal capacity of stem cells and tumorigenesis (88). An alternative concept is emerging that suggests the primary functions of activated oncogenes and inactivated tumor suppressors as mediators of cellular rewiring. An increased expression of LDH-A upon c-Myc activation emphasized the role of c-Myc in the regulation of glycolysis (89). Subsequent studies have shown that various enzymes indispensable for glucose metabolism such as GLUT1, HK2, PFKM, PKM2, PDK1, and ENO1 are also found to be regulated by c-Myc and directly contribute to aerobic glycolysis (90, 91). It is interesting that activation of c-Myc also induces glutaminolysis (92).

Another class of tumor suppressor genes, critical for regulating cell proliferation in a controlled manner in breast cancer, is BRCA, which repairs damaged DNA to maintain the integrity of the genetic material (93). BRCA1 contributes to various metabolic modifications in cancer cells including inhibition of glycolysis and activation of TCA cycle and oxidative

phosphorylation (94). BRCA1 is also known to inhibit energy-consuming anabolic processes such as lipid biosynthesis in cancer cells by interacting with the phosphorylated form of acetyl coenzyme A carboxylase alpha (ACCA), the rate-limiting enzyme that catalyzes *de novo* fatty acid biogenesis (95). This altered metabolic programming allows the cells to maintain a low energy status and controls the excessive proliferation that is a hallmark of cancer cells. A recent report also indicates crosstalk between BRCA1 and SIRT1, known to modulate energy metabolism (96). BRCA1 mutations are also the major hereditary factors responsible for a large fraction of inherited breast cancers; they account for a 40-85% lifetime risk of female breast cancer (97). BRCA1 has been shown to mediate its effects by interacting with a multitude of key cellular proteins such as p53, c-Myc, Akt (98), HIF1 α (99, 100), and acetyl-CoA carboxylase (ACC) (101) and by controlling the turnover of these target proteins, including p-ACC, HIF1 α , and p-Akt.

Signaling Pathway-mediated Metabolic Reprogramming

EGFR Signaling in Cancer—Growth factor-mediated signaling has been extensively implicated in tumorigenesis, EGFR being a central mediator. EGFR signaling is reported to reprogram the metabolic machinery of cancer cells so as to augment the production of glycolytic intermediates that favor tumor growth (102). A recent report indicated that EGFR signaling simultaneously results in activation of the first step (HK2) and impedes the last step of glycolysis (PKM2), to result in accumulation of glycolytic intermediates in TNBC cells (102). Fructose-1,6-bisphosphate, one such intermediate, functions as an activator of EGFR and provides feed-forward signaling to maintain the shift in the metabolic pathways in cancer cells (102). Constitutive activation of EGFR signaling is driven by mutations in the EGFR tyrosine kinase domain (103).

PI3K/AKT Signaling—The PI3K/Akt signaling pathway is inappropriately activated in many cancers. Mutations in growth factors have been implicated in the hyperactivation of Ras in cancer cells that further results in activation of effector pathways such as the PI3K/Akt pathway (104, 105). The PI3K/Akt pathway is also activated by two major mechanisms including receptor tyrosine kinases and somatic mutations in the signaling pathways (106, 107). Activation of Akt results in the major metabolic reprogramming in tumor cells necessary for tumor cell proliferation and progression. The PI3K/Akt pathway promotes glycolysis through multiple mechanisms. Akt enhances the membrane localization of GLUT1 (108), phosphorylates and activates PFK-2 (109), and it increases the translocation of hexokinase to mitochondria, which elicits glycolytic flux (110). PI3K/Akt/MAPK has also been implicated in lipid biosynthesis by phosphorylation and regulation of ACLY and fatty acid synthase (FAS) enzymes (111, 112).

Metabolic Reprogramming Mediated by the Tumor Microenvironment

The tumor microenvironment undergoes a series of biochemical changes such as hypoxia, depletion of glucose, high levels of lactate, and acidic pH (113, 114). Of these changes, hypoxia is widely established as a hallmark of the tumor microenvironment. The cellular adaptive response to low oxygen tension, such as activation of gene expression programs controlling glucose uptake, metabolism, cell proliferation, and differentiation, is largely regulated by HIF-1 α and HIF-2 α (115, 116). The targets of hypoxia-mediated metabolic

regulation include the glucose transporters GLUT1 and GLUT3, 6-Phosphofructo-2-kinase (PFKFB1), a key regulator of fructose-2,6-bisphosphate (Fru-2,6-BP), which regulates glycolytic flux (117-119). The glycolytic enzymes, phosphoglycerate kinase 1 (PGK 1) and pyruvate kinase M2 (PKM2) are known to be regulated transcriptionally by HIF-1 α (120). HIF-1 α also regulates the monocarboxylate transporter, MCT4 required for lactic acid efflux from cancer cells (121). In addition to its trans-activating role, HIF-1 α actively suppresses metabolism by directly trans-activating the gene-encoding pyruvate dehydrogenase kinase 1 (PDK1); this kinase prevents the pyruvate oxidative decarboxylation to acetyl-CoA and reduces pyruvate entry into the TCA cycle (122). The controlled transactivation of these genes by HIF-1 α reprograms the intracellular fate of glucose (123). Clearly, then, the initiation and progression of tumorigenesis is promoted by HIF signaling. HIF-1 α is activated in cancer cells by loss of function of tumor suppressor (e.g., VHL) and gain of function of oncogenes (leading to PI3K/AKT/mTOR activity) and mediates the metabolic alterations that drive cancer progression (124, 125). In addition to the signaling pathways, HIF-1 α is also methylated by SET7/9 methyltransferase, and lysine-specific demethylase 1 reverses its methylation (126). Systematic meta-analysis based on 40 case-control studies has revealed that polymorphisms in *HIF-1A* at C1772T and G1790A may contribute to increased cancer susceptibility in breast cancer, lung cancer, pancreatic cancer, and oral cancer (127, 128).

Metabolic gene mutations as differential predictors of cancer risk

Racial disparity in allele frequency attributed to cancer risk can arise either from acquired somatic mutations or inherited germline mutations. While somatic mutations are a result of complex environmental interactions, germline mutation, such as founder mutations, determine in part the selective enrichment of mutant alleles in related populations (Figure 3 & Table 1) (5). Founder mutations in oncogenes are passed on from ancestors to descendants in specific populations, rendering them at greater risk of cancer. For example, founder mutations of *BRCA1/2* genes found in Ashkenazic Jews and Icelandic populations account for approximately 3-10% of all breast cancers in the general population, and it has been demonstrated that founder germline mutations impart differential cancer susceptibility in different racial groups. The prevalence of the *BRCA2* 999del5 mutation in the Icelandic population, for example, is 20 times greater than in that of the general population (129). In another study conducted on colorectal cancer, it was discovered that a lower mutational load appeared in Asians compared to African-Americans and Caucasians (60% vs. 79 & 77%) upon investigation of 385 mutations across 33 known cancer genes. *BRAF* mutations were more prevalent in Caucasians, with the highest frequency observed for the *BRAF* V600E mutation (130).

The molecular subtypes in breast cancer are stratified, based on heterogeneous expression of signaling receptors. As noted above, racial disparity in different sub-types of breast cancer is well established, with maximal disease risk being observed in African-Americans. In a study conducted in 11 immigrant populations from different geographical locations, it was demonstrated that recent immigrant populations had higher disease risk for ER-negative/PR-negative tumors (131). The *BRCA* gene, associated with breast cancer risk, shows contrasting trends in Asian and Caucasian populations. Mutations in the *BRCA1* gene are

more prevalent in Caucasians (67 vs. 42%), while *BRCA2* mutations are more in Asians (58 vs. 37%) (132). Estrogen receptor signaling is crucial in the development of breast cancer. High levels of circulating estrogens and their metabolites have been shown to correlate with an increased risk of breast cancer among postmenopausal women (133). A comparative analysis of patients of European and African descent showed significant association in SNPs of *ESR1* gene (rs1801132, rs2046210, and rs3020314) in ER-positive breast cancers in European women. GWAS studies conducted in Asian population show association of SNP rs2046210, although its association in African-American population has not been investigated (134).

Racial disparity in the stratification of cancer risk is well associated with mutations in key oncoregulators. According to the Lung Cancer Mutation Consortium 1 database, an analysis of 10 key oncogenes revealed higher rates of oncogenic drivers in Asian patients, while frequent mutations of *KRAS* and *EGFR* genes were found in African-American patients (135). *KRAS* mutations have also been associated with different stages in the progression of lung adenocarcinomas. *KRAS* transcripts from the minor allele for KRAS-1 and -6 polymorphisms severely affected oncogenic signaling than those having the major allele (136). Genetic mutations in the different populations not only vary at different positions in the gene but can also vary in insertion types. Approximately 27% of mutations in *KRAS* genes are found at either codon 12 or 13. The majority of these mutations result in the insertion of cysteine; however, rare insertions of valine, glycine and serine were observed in African-Americans at a higher rate than Caucasians (137). A recent report has also shown significantly higher rates of the *KRAS* G12V mutation in the African-Americans as compared to the Caucasians (138). *KRAS* mutations in colorectal cancer are more frequently found in African-Americans than Caucasians (37% vs. 21) and were associated with advanced stage (odds ratio = 3.3) and tumor grade (odds ratio = 5.60) in African-Americans (139). Higher mutation rates in *KRAS* gene were also observed in pancreatic neuroendocrine tumors of Chinese patients than Caucasian (140). *EGFR* mutations are well associated with different races in non-small cell lung cancers (141). The lower frequency of *EGFR* mutations are reported in African-American patients compared to Caucasians; however, no difference is observed in the frequency of L858R mutations (142). Activating *EGFR* mutations are also critical indicators for response to therapy. Higher rates of *EGFR* mutation frequency are observed in East-Asian patients along with the relatively higher frequency of exon 19 deletions and L858R mutation (143). *EGFR* mutations were also observed in US Hispanic and Non-Hispanics, although their rates were similar between both the groups (144). Association of oncogenic *KRAS* and *EGFR* mutations with somatic mutations in the signaling molecules, *LKB1* and *HER2* genes, have been addressed in various racial populations. *HER2* is a tumor promoting gene that belongs to the *EGFR* family of receptor tyrosine kinases while *LKB1* is a tumor suppressor serine-threonine kinase. The mutational hotspot in the *HER2* gene at 776–779 bases was found to exist differentially in Asian and Caucasian patients. Further, *EGFR*, *HER2*, and *KRAS* mutations were mutually exclusive in Caucasian lung adenocarcinoma patients (145). While amplification and overexpression of *HER2* gene has been implicated in multiple cancers, the loss of *LKB1* has been previously reported to promote metabolic reprogramming by regulating HIF-1 α through mTORC1 and reactive oxygen species (146). *LKB1* mutations

were also found in different frequencies in Caucasian and East Asian populations; however, no significant associations were established among these populations due to small sample size (147).

PIK3CA and *BRAF* mutations can also influence colorectal cancer risk with significantly higher rates of *PIK3CA* mutations being associated with higher mortality rates in African-Americans (139). Mutations of the tumor suppressor gene, *p53*, are used to study the effects of carcinogens in the development of cancers. Mutations resulting in A:T→G:C transitions were more prevalent in African-Americans than Caucasians (148). The prominent diversity in the *p53* mutational landscape was also reflected in 15 geographically and ethnically diverse populations (149).

Mutations in metabolic enzymes can also be linked with stratified cancer risk. Genetic alterations in metabolic enzymes of TCA cycle were recently linked to risk and overall survival in different types of cancer. Mutations found in two key enzymes *SDHC* (rs4131826) and *FH* (rs12071124) were significantly associated with the survival time of colorectal cancer patients (150). Cigarette smoking, the major risk factor for lung cancer, is also associated with differential risk in smokers from different racial backgrounds. Cancer risk in African-American patients is associated with higher levels of the two phenanthrene metabolites, 3-hydroxyphenanthrene (3-PheOH), and phenanthrenetetraol (PheT) found in cigarette smoke, as compared to other populations. Further, polymorphism in the *GSTT2* gene was associated with PheT levels; however, the mutation was not significantly associated in different racial groups (151). In another study on similar lines, the proportion of nicotine metabolic pathways (C-oxidation, N-glucuronidation, and N-oxidation) upon correlation with *UGT2B10* genotype demonstrated different metabolic patterns in five ethnic populations. The *UGT2B10* splice variant (rs116294140) was associated with low levels of nicotine and N-glucuronidation in the African-American persons studied (152). These two studies lay the foundation for conducting integrative metabolic and genetic studies to unravel informative differences between diverse ethnic groups in future.

Metabolic Profiles as Discriminators of Cancer Risk in Different Racial Groups

Different genetic mutational signatures are associated with various forms of tumors; however, the regulation of core metabolic machinery is a central feature of all of them. Metabolomic hallmarks of cancer include Warburg effect, enhanced glycolysis, glutaminolysis, and gluconeogenesis along with suppression of Krebs cycle and lipid catabolism (9). Advances in metabolomics research have enabled the possibility of using metabolomic profiles as biomarkers of early detection, tumor characterization, and clinical outcome prediction. Global metabolic profiles of paired tumor samples from liver, breast, and pancreas identified metabolites unique to each tissue and cancer type with significant differences observed in lipid and amino acid pathways (153). Colorectal tumor tissues exhibit significantly higher levels of C16 and C24 ceramides and endocannabinoid compared to adjacent non-tumor tissues (154).

Metabolomic signatures can also distinguish different disease states based on an analysis of serum metabolites. Blood plasma or serum has been extensively used in different cancer types, such as breast, colorectal, pancreatic, and lung cancers to delineate metabolic markers (155, 156). Metabolic profiling of sera from pancreatic cancer patients and healthy subjects showed alterations in levels of 206 metabolites capable of discriminating disease states (157, 158). Further, metabolomic analysis of the pancreatic cancer patient's serum from Japanese and Caucasian populations demonstrated lower levels of serum phospholipids and ultra-long-chain fatty acid, PC-594 (159). Another study on metabolomic analysis of 38 pancreatic cell lines discriminated all pancreatic ductal adenocarcinoma into three distinct metabolic subtypes, characterized by reduced proliferative capacity and glycolytic and lipogenic profiles (160). Metabolic differences in benign and metastatic pulmonary nodules also discriminated different stages of lung cancer (161). In another study, metabolite profiling of lung carcinomas distinguished lung adenocarcinomas from squamous cell carcinoma by a metabolic signature consisting of 13 metabolites. Adenocarcinomas demonstrated elevated phospholipid metabolism and protein catabolism, whereas stronger glycolytic and glutaminolytic profiles were observed in squamous cell carcinomas (162). Further, phospholipidomic analysis of malignant and non-malignant lung tissues from 162 non-small cell lung cancer patients identified 91 differentially expressed phospholipids with prominent changes detected in sphingomyelins and phosphatidylinositols (163). Serum metabolomic profiles from colorectal adenocarcinoma patients were also able to distinguish different stages of metastases (164). Metabolic changes in colonic tissues, including tumor, polyps, and adjacent matched normal mucosa from 26 patients investigated during colorectal cancer progression, revealed elevated levels of amino acids and lipids, especially carnitine metabolites in the polyps and tumors (26).

Metabolic studies on breast cancers subtypes show different profiles based on growth factor receptor expression. Triple-negative breast cancers (TNBC) are the most aggressive tumors with no effective therapeutic intervention (165). Metabolite choline, which is associated with cell proliferation and oncogenic signaling, was found to be significantly altered, as was glutaminolysis in triple-negative and triple-positive breast cancer patients (166). Furthermore, a metabolomic comparison of TNBC with estrogen receptor-positive breast carcinomas in African-American patients identified significant differences in 133 metabolites involved in increased methionine uptake and transmethylation reactions resulting in elevated levels of methylated nucleic acids and amino acids. Also, elevated levels of oncometabolites (sarcosine and 2-hydroxyglutarate) were detected, though their significance in breast cancer is not understood (24). Another metabolomic study conducted on 204 estrogen receptor-positive and 67 estrogen receptor-negative breast cancer tissues found 19 altered metabolites with significant changes in beta-alanine, 2-hydroxyglutarate, glutamate, xanthine, and glutamine (167). African-American women have shown higher incidences of more aggressive TNBC with poor survival rate as compared to Caucasian women. To understand the differences in the prevalence of breast cancer in different races, microarray profiling done in 23 African-American and 34 Caucasian triple-negative breast cancer women revealed no drastic difference in expression of genes except *CRYBB2P1* pseudogene (168).

Genic mutations in oncoregulators can modulate metabolite levels by differentially regulating signaling cascades. Since the genic mutational frequency is differentially associated with various races, this frequency can translate to differences in oncometabolite levels. Mutations in *KRAS* oncoregulators are frequently found in pancreatic, colon, and lung cancers. *KRAS* mutations found in codon-12 (G12C, G12D, G12V) are associated with different metabolomic profiles compared to the *KRAS*^{WT} gene and have lower amounts of glutamine, asparagine, and proline. Mutant G12C had the largest number of specific unique metabolites, with *KRAS*^{G12C} showing a significant increase in L-alpha-aminobutyric acid, a precursor metabolite associated with oxidative stress (169). Of interest, it was found that genetic variations in humans can only account for 12% of the observed variation in metabolic homeostasis (170). While genetic factors can partly explain the racial disparity in the heritability for cancer risk, metabolite profiling can be an alternative approach for dissecting this anomaly. A case-control study conducted on 60 breast cancer patients found 78 discriminatory metabolites belonging to amino acids, fatty acids, and lysolipids in both the racial groups compared to healthy controls (171). As opposed to earlier research on cancer metabolism focused on the regulation of core metabolic pathways, shifting research focus on understanding the role of metabolic oncogenes and metabolic regulation in different races can unravel novel metabolic markers.

Racial Disparity in Genetic Regulation of Cancer Prognosis And Therapy

Genetic variation in different populations, confer differential susceptibility to risk or prevention of cancer, and therefore clinical outcomes for common cancers are also determined by the genetic backgrounds of racial and ethnic groups (172). With emerging statistics detailing the disparities in cancer prevalence among different races, particularly African-Americans (some reasons for which are poorly defined) (23, 173), it is critical to understand the underlying mechanisms for racial groups to best apply therapeutic interventions. Genome-wide mutation analysis studies have enabled the identification of the differential incidence of somatic gene mutations in key oncogenic drivers and metabolic enzymes in cancer pathogenesis. The temporal differences in survival of cancer patients can be attributed to observed variation in modified genetic make-up of cancer cells. A promoter polymorphism of the myeloperoxidase gene *MPO* (463G→A), a key enzyme in tobacco-induced carcinogenesis, was shown to decrease lung cancer susceptibility in small cell lung cancer (174, 175). In another instance, analysis of Stage II and III breast cancer patients clearly demonstrated a poorer survival outcome in African-American patients compared to other racial groups. Further investigation revealed the genetic composition of susceptible African-American patients to involve ER⁺/PR⁺/HER2⁻, the presence of which resulted in diminished survival among African-American women patients (176).

Differences in susceptibility to the effects of chemotherapy, commonly termed as pharmacoethnicity, among racial and ethnic groups, can also regulate therapeutic outcomes in the administration of anti-cancer drugs. Recent advances in clinical research have explored predictive clinical and molecular factors for cancer therapies in patients with diverse cancer phenotypes. Genetic polymorphism studies have revealed a plethora of such candidate genes. Somatic mutations in the *EGFR* gene were identified in the NSCLC patients from Japan and United States with a prevalence rate of 26% and 1.6% respectively

(177). The genetic polymorphism of the *hENT1* gene 706G→C has been associated with reduced response to gemcitabine chemotherapy and with the prognosis of NSCLC (178). Remarkably, metabolomic studies in breast cancer have revealed that patients with allelic variations in *CYP2D6*, *SULT1A2*, *UGT1A4*^{48Val} and *UGT2B7*^{268Tyr} as best candidates for the optimal therapeutic response to tamoxifen, a chemotherapeutic prodrug, the hydroxylated and non-glucuronidated form of which exerts anti-estrogen effects during the treatment of estrogen-dependent breast cancer (179). These examples distinctly indicate a link between inherited genetic differences to therapy responses by specific drugs.

In addition to genetic polymorphisms in drug metabolizing enzymes, inherited variations in genes involved in metabolism, DNA repair, and drug transport may also contribute to differential outcomes of cancer treatment (180, 181). Mutation spectrum analysis of samples from metastatic colorectal cancer undergoing a phase III clinical trial for the VEGF inhibitor cediranib indicated the association between glycolytic and hypoxic gene expression profiles with improved clinical outcome in patients treated with cediranib (182).

A detailed analysis of oncogenic driver mutation in *KRAS* and *BRAF* genes was performed in node-positive colon cancer patients of different races including Asians, African-Americans, and Caucasians. Association of the race with clinicopathological characteristics revealed that the BRAFV600E mutation frequency was almost twice that of Asians and African-Americans. However, *KRAS* mutation rates were highest in African-Americans (44.1%). Moreover, the wild type forms of *KRAS* and *BRAF* were most common among Asians (183). Typically, the BRAFV600E mutations forecast adverse prognosis and the *KRAS* mutations predict resistance to EGFR inhibitors in advanced disease. Detailed analysis of *BRAF* mutations in 697 patients with lung adenocarcinomas has shown the prevalence rate to be approximately 2.58%. The identified mutations were V600E, G469A, and D594G and intriguingly, all the patients carrying the mutations were Caucasians (184). In a Chinese colorectal cancer patient cohort study, high frequency of *KRAS* mutation (31%) was observed which in turn altered the clinical efficacy of the EGFR-TK inhibitor therapy using cetuximab (185). *KRAS* mutation prevalence analysis in Chinese NSCLC patients revealed relatively lower mutation rate as compared to Caucasian patients (3.8-8% vs. 18-26%) (143, 186-189). Thus, understanding of the mutations in *KRAS* is critical for selection of optimal drug therapies in distinct patient groups.

Mutations in oncogenes like *Myc* and tumor-suppressor genes like *p53* drastically alter cancer physiology and survival by reprogramming cellular metabolism and mitochondrial biogenesis (80). An unbiased metabolomics approach to elucidate metabolic signatures and differences between African-American and European-American breast cancer patients was conducted. Of note, prominent elevation in the levels of 2-HG; which is linked to *Myc* activation and glutamine dependence, was observed in the African-American population (190).

Along with the incidence of oncogenic mutations, the efficacy of cancer targeting approaches is strikingly affected by metabolic heterogeneity of mutant cells. It was recently demonstrated that advanced lung tumors acquired a mutant copy of *KRAS* (*KRAS*^{G12D/G12D} homozygotes) pertinent to malignant progression of tumor cells. *KRAS*^{G12D/G12D}

homozygotes exhibited a glycolytic switch and were highly sensitive to the glucose analog, 2-deoxy-D-glucose compared to early stage lung tumors (KRAS^{G12D/WT} heterozygotes), which displayed increased sensitivity to low glutamine. Clearly, the mutant KRAS lung tumor is heterogeneous in nature, exhibiting bivariate metabolic profiles and prognosis, and demanding unique drug therapies to selectively target hostile tumor cells based on the differences in mutant allelic content (76).

We believe that genetic mutations observed within different racial and ethnic groups can also identify treatment responses to chemotherapeutic and radiotherapeutic interventions and prognosis of cancer. With the advent of molecularly targeted therapies for diverse cancer treatments, it is rational to consider racial differences in specific genetic and genomic alterations that have implications in the choices of therapeutics and subsequent development of drug sensitivity/resistance profiles.

Conclusion

Race and ethnicity are subjective matters, since they are determined or accepted based upon declared racial and ethnic status, patterns of human migration and admixture of populations. Populations are classified into different groups on the basis of common ancestral pedigree and geographical barriers. Racial cohorts belonging to the same geographical location are exposed to similar environmental cues and carcinogens, and thus present a high probability of harboring an induced mutation (191). Recent studies in the field of cancer suggest a very strong association of genetic polymorphisms with differential rates of cancer incidence, prevalence, and mortality (192). Racial differences in natural genetic variations can be used as a classifier of cancer risk. However, very few studies have addressed the connection between metabolic pathways and genetic mutations in metabolic enzymes and their regulators. Metabolic reprogramming in cancer cells is critical for tumor progression and metastasis (9). This review summarizes how mutations in proto-oncogenes and tumor suppressor genes alter the regulation of signal transduction pathways to reprogram cellular metabolism required to support anabolic growth. Furthermore, the oncogenic roles of metabolites have also been demonstrated to alter signaling pathways and regulate cellular differentiation. Apart from mutations in metabolic enzymes and regulators, metabolites themselves can serve as discriminators for cancer risk in different races. This review also suggests the potential of population-specific candidate mutations and metabolomic differences, whether explored or unexplored, in discriminating cancer risk, prognosis and predicting efficacy of therapeutic interventions in different human races. Clearly, there is a need to conduct focused studies on metabolic profiling in conjunction with genome-wide mutation analysis in different human races so as to unravel novel molecular determinants of cancer risk and chemotherapeutic susceptibility.

Acknowledgments

This work was supported in part by funding from the National Institutes of Health grant (R01 CA163649, NCI) to PKS, and the Specialized Programs for Research Excellence (SPOR, 2P50 CA127297, NCI) to PKS.

References

1. Rosenberg NA, Huang L, Jewett EM, Szpiech ZA, Jankovic I, Boehnke M. Genome-wide association studies in diverse populations. *Nat Rev Genet.* 2010; 11(5):356–66. DOI: 10.1038/nrg2760 [PubMed: 20395969]
2. Lee JC, Parkes M. Genome-wide association studies and Crohn's disease. *Brief Funct Genomics.* 2011; 10(2):71–6. DOI: 10.1093/bfgp/eln009 [PubMed: 21436303]
3. Wheeler E, Barroso I. Genome-wide association studies and type 2 diabetes. *Brief Funct Genomics.* 2011; 10(2):52–60. DOI: 10.1093/bfgp/eln008 [PubMed: 21436302]
4. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. *Nature.* 2001; 411(6835): 342–8. DOI: 10.1038/35077213 [PubMed: 11357141]
5. Wiencke JK. Impact of race/ethnicity on molecular pathways in human cancer. *Nat Rev Cancer.* 2004; 4(1):79–84. DOI: 10.1038/nrc1257 [PubMed: 14708028]
6. Macaluso M, Paggi MG, Giordano A. Genetic and epigenetic alterations as hallmarks of the intricate road to cancer. *Oncogene.* 2003; 22(42):6472–8. DOI: 10.1038/sj.onc.1206955 [PubMed: 14528270]
7. Loeb KR, Loeb LA. Significance of multiple mutations in cancer. *Carcinogenesis.* 2000; 21(3):379–85. [PubMed: 10688858]
8. Dong LM, Potter JD, White E, Ulrich CM, Cardon LR, Peters U. Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. *JAMA.* 2008; 299(20):2423–36. DOI: 10.1001/jama.299.20.2423 [PubMed: 18505952]
9. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell.* 2011; 144(5):646–74. DOI: 10.1016/j.cell.2011.02.013 [PubMed: 21376230]
10. Allen E, Mievillie P, Warren CM, Saghafeinia S, Li L, Peng MW, Hanahan D. Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling. *Cell Rep.* 2016; 15(6):1144–60. DOI: 10.1016/j.celrep.2016.04.029 [PubMed: 27134166]
11. Stalneck CA, Ulrich SM, Li Y, Ramachandran S, McBrayer MK, DeBerardinis RJ, Cerione RA, Erickson JW. Mechanism by which a recently discovered allosteric inhibitor blocks glutamine metabolism in transformed cells. *Proc Natl Acad Sci U S A.* 2015; 112(2):394–9. DOI: 10.1073/pnas.1414056112 [PubMed: 25548170]
12. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, Casimiro MC, Wang C, Fortina P, Addya S, Pestell RG, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. *Cell Cycle.* 2009; 8(23):3984–4001. DOI: 10.4161/cc.8.23.10238 [PubMed: 19923890]
13. Boroughs LK, DeBerardinis RJ. Metabolic pathways promoting cancer cell survival and growth. *Nat Cell Biol.* 2015; 17(4):351–9. DOI: 10.1038/ncb3124 [PubMed: 25774832]
14. Alizadeh AA, Aranda V, Bardelli A, Blanpain C, Bock C, Borowski C, Caldas C, Califano A, Doherty M, Elsner M, Esteller M, Fitzgerald R, Korbel JO, Lichter P, Mason CE, Navin N, Pe'er D, Polyak K, Roberts CW, Siu L, Snyder A, Stower H, Swanton C, Verhaak RG, Zenklusen JC, Zuber J, Zucman-Rossi J. Toward understanding and exploiting tumor heterogeneity. *Nat Med.* 2015; 21(8):846–53. DOI: 10.1038/nm.3915 [PubMed: 26248267]
15. Howlader N, NA.Krapcho, M.Miller, D.Bishop, K.Altekruse, SF.Kosary, CL.Yu, M.Ruhl, J.Tatalovich, Z.Mariotto, A.Lewis, DR.Chen, HS.Feuer, EJ., Cronin, KA., editors. SEER Cancer Statistics Review, 1975-2013. National Cancer Institute; Bethesda, MD: Apr. 2016 http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site
16. McCarthy AM, Yang J, Armstrong K. Increasing disparities in breast cancer mortality from 1979 to 2010 for US black women aged 20 to 49 years. *Am J Public Health.* 2015; 105(Suppl 3):S446–8. DOI: 10.2105/AJPH.2014.302297 [PubMed: 25905842]
17. Maisonneuve P, Lowenfels AB. Risk factors for pancreatic cancer: a summary review of meta-analytical studies. *Int J Epidemiol.* 2015; 44(1):186–98. DOI: 10.1093/ije/dyu240 [PubMed: 25502106]

18. Johnson CM, Wei C, Ensor JE, Smolenski DJ, Amos CI, Levin B, Berry DA. Meta-analyses of colorectal cancer risk factors. *Cancer Causes Control*. 2013; 24(6):1207–22. DOI: 10.1007/s10552-013-0201-5 [PubMed: 23563998]
19. Gong Z, Ambrosone CB, McCann SE, Zirpoli G, Chandran U, Hong CC, Bovbjerg DH, Jandorf L, Ciupak G, Pawlish K, Lu Q, Hwang H, Khoury T, Wiam B, Bandera EV. Associations of dietary folate, Vitamins B6 and B12 and methionine intake with risk of breast cancer among African American and European American women. *Int J Cancer*. 2014; 134(6):1422–35. DOI: 10.1002/ijc.28466 [PubMed: 23996837]
20. Gram IT, Park SY, Kolonel LN, Maskarinec G, Wilkens LR, Henderson BE, Le Marchand L. Smoking and Risk of Breast Cancer in a Racially/Ethnically Diverse Population of Mainly Women Who Do Not Drink Alcohol: The MEC Study. *Am J Epidemiol*. 2015; 182(11):917–25. DOI: 10.1093/aje/kwv092 [PubMed: 26493265]
21. DeSantis CE, Siegel RL, Sauer AG, Miller KD, Fedewa SA, Alcaraz KI, Jemal A. Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities. *CA Cancer J Clin*. 2016; 66(4):290–308. DOI: 10.3322/caac.21340 [PubMed: 26910411]
22. Curran JN, Garrett-Mayer E, Carpenter MJ, Ford ME, Silvestri GA, Lackland DT, Alberg AJ. Cigarette smoking and the risk of dying from tobacco-related malignancies by race. *Anticancer Res*. 2011; 31(11):3891–5. [PubMed: 22110215]
23. Haiman CA, Stram DO, Wilkens LR, Pike MC, Kolonel LN, Henderson BE, Le Marchand L. Ethnic and racial differences in the smoking-related risk of lung cancer. *N Engl J Med*. 2006; 354(4):333–42. DOI: 10.1056/NEJMoa033250 [PubMed: 16436765]
24. Kanaan YM, Sampey BP, Beyene D, Esnakula AK, Naab TJ, Ricks-Santi LJ, Dasi S, Day A, Blackman KW, Frederick W, Copeland RL Sr, Gabrielson E, Dewitty RL Jr. Metabolic profile of triple-negative breast cancer in African-American women reveals potential biomarkers of aggressive disease. *Cancer Genomics Proteomics*. 2014; 11(6):279–94. [PubMed: 25422359]
25. Tsai CJ, Giovannucci EL. Hyperinsulinemia, insulin resistance, vitamin D, and colorectal cancer among whites and African Americans. *Dig Dis Sci*. 2012; 57(10):2497–503. DOI: 10.1007/s10620-012-2198-0 [PubMed: 22562539]
26. Ong ES, Zou L, Li S, Cheah PY, Eu KW, Ong CN. Metabolic profiling in colorectal cancer reveals signature metabolic shifts during tumorigenesis. *Mol Cell Proteomics*. 2010; doi: 10.1074/mcp.M900551-MCP200
27. Cavicchia PP, Adams SA, Steck SE, Hussey JR, Liu J, Daguise VG, Hebert JR. Racial disparities in colorectal cancer incidence by type 2 diabetes mellitus status. *Cancer Causes Control*. 2013; 24(2):277–85. DOI: 10.1007/s10552-012-0095-7 [PubMed: 23197224]
28. Murphy CC, Martin CF, Sandler RS. Racial differences in obesity measures and risk of colorectal adenomas in a large screening population. *Nutr Cancer*. 2015; 67(1):98–104. DOI: 10.1080/01635581.2015.976316 [PubMed: 25425186]
29. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. *Nat Rev Cancer*. 2002; 2(12):897–909. DOI: 10.1038/nrc949 [PubMed: 12459728]
30. Arnold LD, Patel AV, Yan Y, Jacobs EJ, Thun MJ, Calle EE, Colditz GA. Are racial disparities in pancreatic cancer explained by smoking and overweight/obesity? *Cancer Epidemiol Biomarkers Prev*. 2009; 18(9):2397–405. DOI: 10.1158/1055-9965.EPI-09-0080 [PubMed: 19723915]
31. Silverman DT, Hoover RN, Brown LM, Swanson GM, Schiffman M, Greenberg RS, Hayes RB, Lillemoe KD, Schoenberg JB, Schwartz AG, Liff J, Pottern LM, Fraumeni JF Jr. Why do Black Americans have a higher risk of pancreatic cancer than White Americans? *Epidemiology*. 2003; 14(1):45–54. DOI: 10.1097/01.EDE.0000034393.39604.FF [PubMed: 12500045]
32. Li D, Tang H, Hassan MM, Holly EA, Bracci PM, Silverman DT. Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies. *Cancer Causes Control*. 2011; 22(2):189–97. DOI: 10.1007/s10552-010-9686-3 [PubMed: 21104117]
33. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. *Nat Rev Cancer*. 2011; 11(2):85–95. DOI: 10.1038/nrc2981 [PubMed: 21258394]
34. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science*. 2009; 324(5930):1029–33. DOI: 10.1126/science.1160809 [PubMed: 19460998]

35. Adekola K, Rosen ST, Shanmugam M. Glucose transporters in cancer metabolism. *Curr Opin Oncol.* 2012; 24(6):650–4. DOI: 10.1097/CCO.0b013e328356da72 [PubMed: 22913968]
36. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. *Annu Rev Cell Dev Biol.* 2011; 27:441–64. DOI: 10.1146/annurev-cellbio-092910-154237 [PubMed: 21985671]
37. Vander Heiden MG, Lunt SY, Dayton TL, Fiske BP, Israelsen WJ, Mattaini KR, Vokes NI, Stephanopoulos G, Cantley LC, Metallo CM, Locasale JW. Metabolic pathway alterations that support cell proliferation. *Cold Spring Harb Symp Quant Biol.* 2011; 76:325–34. DOI: 10.1101/sqb.2012.76.010900 [PubMed: 22262476]
38. Porporato PE, Dhup S, Dadhich RK, Copetti T, Sonveaux P. Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. *Front Pharmacol.* 2011; 2:49.doi: 10.3389/fphar.2011.00049 [PubMed: 21904528]
39. Patra KC, Hay N. The pentose phosphate pathway and cancer. *Trends Biochem Sci.* 2014; 39(8): 347–54. DOI: 10.1016/j.tibs.2014.06.005 [PubMed: 25037503]
40. Atsumi T, Chesney J, Metz C, Leng L, Donnelly S, Makita Z, Mitchell R, Bucala R. High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. *Cancer Res.* 2002; 62(20):5881–7. [PubMed: 12384552]
41. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. *Cancer Cell.* 2006; 9(6):425–34. DOI: 10.1016/j.ccr.2006.04.023 [PubMed: 16766262]
42. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. *Nature.* 2008; 452(7184):230–3. DOI: 10.1038/nature06734 [PubMed: 18337823]
43. Vazquez A, Liu J, Zhou Y, Oltvai ZN. Catabolic efficiency of aerobic glycolysis: the Warburg effect revisited. *BMC Syst Biol.* 2010; 4:58.doi: 10.1186/1752-0509-4-58 [PubMed: 20459610]
44. Gray LR, Tompkins SC, Taylor EB. Regulation of pyruvate metabolism and human disease. *Cell Mol Life Sci.* 2014; 71(14):2577–604. DOI: 10.1007/s00018-013-1539-2 [PubMed: 24363178]
45. Lin R, Tao R, Gao X, Li T, Zhou X, Guan KL, Xiong Y, Lei QY. Acetylation stabilizes ATP-citrate lyase to promote lipid biosynthesis and tumor growth. *Mol Cell.* 2013; 51(4):506–18. DOI: 10.1016/j.molcel.2013.07.002 [PubMed: 23932781]
46. Munoz-Pinedo C, El Mjiyad N, Ricci JE. Cancer metabolism: current perspectives and future directions. *Cell Death Dis.* 2012; 3:e248.doi: 10.1038/cddis.2011.123 [PubMed: 22237205]
47. van Geldermalsen M, Wang Q, Nagarajah R, Marshall AD, Thoeng A, Gao D, Ritchie W, Feng Y, Bailey CG, Deng N, Harvey K, Beith JM, Selinger CI, O'Toole SA, Rasko JE, Holst J. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. *Oncogene.* 2016; 35(24):3201–8. DOI: 10.1038/onc.2015.381 [PubMed: 26455325]
48. Dang CV. Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. *Cancer Res.* 2010; 70(3):859–62. DOI: 10.1158/0008-5472.CAN-09-3556 [PubMed: 20086171]
49. Wen D, Liu D, Tang J, Dong L, Liu Y, Tao Z, Wan J, Gao D, Wang L, Sun H, Fan J, Wu W. Malic enzyme 1 induces epithelial-mesenchymal transition and indicates poor prognosis in hepatocellular carcinoma. *Tumour Biol.* 2015; 36(8):6211–21. DOI: 10.1007/s13277-015-3306-5 [PubMed: 25753478]
50. DeBerardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. *Curr Opin Genet Dev.* 2008; 18(1):54–61. DOI: 10.1016/j.gde.2008.02.003 [PubMed: 18387799]
51. Metallo CM, Gameiro PA, Bell EL, Mattaini KR, Yang J, Hiller K, Jewell CM, Johnson ZR, Irvine DJ, Guarente L, Kelleher JK, Vander Heiden MG, Iliopoulos O, Stephanopoulos G. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. *Nature.* 2012; 481(7381): 380–4. DOI: 10.1038/nature10602
52. Mullen AR, Wheaton WW, Jin ES, Chen PH, Sullivan LB, Cheng T, Yang Y, Linehan WM, Chandel NS, DeBerardinis RJ. Reductive carboxylation supports growth in tumour cells with defective mitochondria. *Nature.* 2012; 481(7381):385–8. DOI: 10.1038/nature10642

53. Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, Perera RM, Ferrone CR, Mullarky E, Shyh-Chang N, Kang Y, Fleming JB, Bardeesy N, Asara JM, Haigis MC, DePinho RA, Cantley LC, Kimmelman AC. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. *Nature*. 2013; 496(7443):101–5. DOI: 10.1038/nature12040 [PubMed: 23535601]
54. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, Thompson CB. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. *Proc Natl Acad Sci U S A*. 2007; 104(49): 19345–50. DOI: 10.1073/pnas.0709747104 [PubMed: 18032601]
55. Yang C, Ko B, Hensley CT, Jiang L, Wasti AT, Kim J, Sudderth J, Calvaruso MA, Lumata L, Mitsche M, Rutter J, Merritt ME, DeBerardinis RJ. Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport. *Mol Cell*. 2014; 56(3):414–24. DOI: 10.1016/j.molcel.2014.09.025 [PubMed: 25458842]
56. Vaughn AE, Deshmukh M. Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c. *Nat Cell Biol*. 2008; 10(12):1477–83. DOI: 10.1038/ncb1807 [PubMed: 19029908]
57. Dong X, Tang H, Hess KR, Abbruzzese JL, Li D. Glucose metabolism gene polymorphisms and clinical outcome in pancreatic cancer. *Cancer*. 2011; 117(3):480–91. DOI: 10.1002/encr.25612 [PubMed: 20845477]
58. Kim SJ, Hwang SH, Kim IJ, Lee MK, Lee CH, Lee SY, Lee EY. The association of 18F-deoxyglucose (FDG) uptake of PET with polymorphisms in the glucose transporter gene (SLC2A1) and hypoxia-related genes (HIF1A, VEGFA, APEX1) in non-small cell lung cancer. SLC2A1 polymorphisms and FDG-PET in NSCLC patients. *J Exp Clin Cancer Res*. 2010; 29:69.doi: 10.1186/1756-9966-29-69 [PubMed: 20540786]
59. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, van der Mey A, Taschner PE, Rubinstein WS, Myers EN, Richard CW 3rd, Cornelisse CJ, Devilee P, Devlin B. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. *Science*. 2000; 287(5454):48–51. [PubMed: 10657297]
60. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, Leigh I, Gorman P, Lamlum H, Rahman S, Roylance RR, Olpin S, Bevan S, Barker K, Hearle N, Houlston RS, Kiuru M, Lehtonen R, Karhu A, Vilkki S, Laiho P, Eklund C, Vierimaa O, Aittomäki K, Hietala M, Sistonen P, Pääta A, Salovaara R, Herva R, Launonen V, Aaltonen LA, Multiple Leiomyoma C. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. *Nat Genet*. 2002; 30(4):406–10. DOI: 10.1038/ng849 [PubMed: 11865300]
61. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD. IDH1 and IDH2 mutations in gliomas. *N Engl J Med*. 2009; 360(8): 765–73. DOI: 10.1056/NEJMoa0808710 [PubMed: 19228619]
62. Guo X, Li D, Wu Y, Chen Y, Zhou X, Wang X, Huang X, Li X, Yang H, Xing J. Genetic variants in genes of tricarboxylic acid cycle key enzymes are associated with prognosis of patients with non-small cell lung cancer. *Lung Cancer*. 2015; 87(2):162–8. DOI: 10.1016/j.lungcan.2014.12.005 [PubMed: 25576295]
63. Pollard PJ, Briere JJ, Alam NA, Barwell J, Barclay E, Wortham NC, Hunt T, Mitchell M, Olpin S, Moat SJ, Hargreaves IP, Heales SJ, Chung YL, Griffiths JR, Dalglish A, McGrath JA, Gleeson MJ, Hodgson SV, Poulson R, Rustin P, Tomlinson IP. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. *Hum Mol Genet*. 2005; 14(15):2231–9. DOI: 10.1093/hmg/ddi227 [PubMed: 15987702]
64. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB, Gottlieb E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF- α prolyl hydroxylase. *Cancer Cell*. 2005; 7(1):77–85. DOI: 10.1016/j.ccr.2004.11.022 [PubMed: 15652751]
65. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, Merino M, Trepel J, Zbar B, Toro J, Ratcliffe PJ, Linehan WM, Neckers L. HIF overexpression correlates with biallelic loss of

- fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. *Cancer Cell*. 2005; 8(2):143–53. DOI: 10.1016/j.ccr.2005.06.017 [PubMed: 16098467]
66. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, Yu W, Li Z, Gong L, Peng Y, Ding J, Lei Q, Guan KL, Xiong Y. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1 α . *Science*. 2009; 324(5924):261–5. DOI: 10.1126/science.1170944 [PubMed: 19359588]
 67. Guo X, Chen C, Liu B, Wu Y, Chen Y, Zhou X, Huang X, Li X, Yang H, Chen Z, Xing J. Genetic variations in monocarboxylate transporter genes as predictors of clinical outcomes in non-small cell lung cancer. *Tumour Biol*. 2015; 36(5):3931–9. DOI: 10.1007/s13277-014-3036-0 [PubMed: 25578492]
 68. Fei F, Guo X, Chen Y, Liu X, Tu J, Xing J, Chen Z, Ji J, He X. Polymorphisms of monocarboxylate transporter genes are associated with clinical outcomes in patients with colorectal cancer. *J Cancer Res Clin Oncol*. 2015; 141(6):1095–102. DOI: 10.1007/s00432-014-1877-y [PubMed: 25492048]
 69. Xie S, Zhou F, Wang J, Cao H, Chen Y, Liu X, Zhang Z, Dai J, He X. Functional polymorphisms of ATP citrate lyase gene predicts clinical outcome of patients with advanced colorectal cancer. *World J Surg Oncol*. 2015; 13:42.doi: 10.1186/s12957-015-0440-x [PubMed: 25890184]
 70. Zhang B, Jia WH, Matsuda K, Kweon SS, Matsuo K, Xiang YB, Shin A, Jee SH, Kim DH, Cai Q, Long J, Shi J, Wen W, Yang G, Zhang Y, Li C, Li B, Guo Y, Ren Z, Ji BT, Pan ZZ, Takahashi A, Shin MH, Matsuda F, Gao YT, Oh JH, Kim S, Ahn YO, Genetics, C. Epidemiology of Colorectal Cancer; Chan AT, Chang-Claude J, Slattery ML, S. Colorectal Transdisciplinary; Gruber SB, Schumacher FR, Stenzel SL, R. Colon Cancer Family. Casey G, Kim HR, Jeong JY, Park JW, Li HL, Hosono S, Cho SH, Kubo M, Shu XO, Zeng YX, Zheng W. Large-scale genetic study in East Asians identifies six new loci associated with colorectal cancer risk. *Nat Genet*. 2014; 46(6):533–42. DOI: 10.1038/ng.2985 [PubMed: 24836286]
 71. Hong SY, Yu FX, Luo Y, Hagen T. Oncogenic activation of the PI3K/Akt pathway promotes cellular glucose uptake by downregulating the expression of thioredoxin-interacting protein. *Cell Signal*. 2016; 28(5):377–83. DOI: 10.1016/j.cellsig.2016.01.011 [PubMed: 26826652]
 72. Ardito CM, Gruner BM, Takeuchi KK, Lubeseder-Martellato C, Teichmann N, Mazur PK, Delgiorno KE, Carpenter ES, Halbrook CJ, Hall JC, Pal D, Briel T, Herner A, Trajkovic-Arsic M, Sipos B, Liou GY, Storz P, Murray NR, Threadgill DW, Sibilia M, Washington MK, Wilson CL, Schmid RM, Raines EW, Crawford HC, Siveke JT. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. *Cancer Cell*. 2012; 22(3):304–17. DOI: 10.1016/j.ccr.2012.07.024 [PubMed: 22975374]
 73. Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D, Hung KE, Flaherty KT, Piris A, Wargo JA, Settleman J, Mino-Kenudson M, Engelman JA. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. *Cancer Discov*. 2012; 2(3):227–35. DOI: 10.1158/2159-8290.CD-11-0341 [PubMed: 22448344]
 74. Iwamoto M, Kawada K, Nakamoto Y, Itatani Y, Inamoto S, Toda K, Kimura H, Sasazuki T, Shirasawa S, Okuyama H, Inoue M, Hasegawa S, Togashi K, Sakai Y. Regulation of 18F-FDG accumulation in colorectal cancer cells with mutated KRAS. *J Nucl Med*. 2014; 55(12):2038–44. DOI: 10.2967/jnumed.114.142927 [PubMed: 25453050]
 75. Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. *Cancer Res*. 2012; 72(10):2457–67. DOI: 10.1158/0008-5472.CAN-11-2612 [PubMed: 22589270]
 76. Kerr EM, Gaude E, Turrell FK, Frezza C, Martins CP. Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities. *Nature*. 2016; 531(7592):110–3. DOI: 10.1038/nature16967 [PubMed: 26909577]
 77. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. *Nature*. 2002; 417(6892):949–54. DOI: 10.1038/nature00766 [PubMed: 12068308]

78. Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, Frederick DT, Hurley AD, Nellore A, Kung AL, Wargo JA, Song JS, Fisher DE, Arany Z, Widlund HR. Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. *Cancer Cell*. 2013; 23(3):302–15. DOI: 10.1016/j.ccr.2013.02.003 [PubMed: 23477830]
79. Vivekananthan DP, Patel VB, Moliterno DJ. Glycoprotein IIb/IIIa antagonism and fibrinolytic therapy for acute myocardial infarction. *J Interv Cardiol*. 2002; 15(2):131–9. [PubMed: 12063808]
80. Yeung SJ, Pan J, Lee MH. Roles of p53, MYC and HIF-1 in regulating glycolysis - the seventh hallmark of cancer. *Cell Mol Life Sci*. 2008; 65(24):3981–99. DOI: 10.1007/s00018-008-8224-x [PubMed: 18766298]
81. Bardeesy N, Aguirre AJ, Chu GC, Cheng KH, Lopez LV, Hezel AF, Feng B, Brennan C, Weissleder R, Mahmood U, Hanahan D, Redston MS, Chin L, Depinho RA. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. *Proc Natl Acad Sci U S A*. 2006; 103(15):5947–52. DOI: 10.1073/pnas.0601273103 [PubMed: 16585505]
82. Singh PK, Mehla K, Hollingsworth MA, Johnson KR. Regulation of Aerobic Glycolysis by microRNAs in Cancer. *Mol Cell Pharmacol*. 2011; 3(3):125–134. [PubMed: 22792411]
83. Boada J, Roig T, Perez X, Gamez A, Bartrons R, Cascante M, Bermudez J. Cells overexpressing fructose-2,6-bisphosphatase showed enhanced pentose phosphate pathway flux and resistance to oxidative stress. *FEBS Lett*. 2000; 480(2-3):261–4. [PubMed: 11034341]
84. Langerod A, Zhao H, Borgan O, Nesland JM, Bukholm IR, Ikdahl T, Karesen R, Borresen-Dale AL, Jeffrey SS. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. *Breast Cancer Res*. 2007; 9(3):R30.doi: 10.1186/bcr1675 [PubMed: 17504517]
85. Wang Y, Helland A, Holm R, Skomedal H, Abeler VM, Danielsen HE, Trope CG, Borresen-Dale AL, Kristensen GB. TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival. *Br J Cancer*. 2004; 90(3):678–85. DOI: 10.1038/sj.bjc.6601537 [PubMed: 14760384]
86. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. *Cold Spring Harb Perspect Biol*. 2010; 2(1):a001008.doi: 10.1101/cshperspect.a001008 [PubMed: 20182602]
87. Scian MJ, Stagliano KE, Ellis MA, Hassan S, Bowman M, Miles MF, Deb SP, Deb S. Modulation of gene expression by tumor-derived p53 mutants. *Cancer Res*. 2004; 64(20):7447–54. DOI: 10.1158/0008-5472.CAN-04-1568 [PubMed: 15492269]
88. Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, Perry SR, Tonon G, Chu GC, Ding Z, Stommel JM, Dunn KL, Wiedemeyer R, You MJ, Brennan C, Wang YA, Ligon KL, Wong WH, Chin L, dePinho RA. Pten and p53 converge on c-Myc to control differentiation, self-renewal, and transformation of normal and neoplastic stem cells in glioblastoma. *Cold Spring Harb Symp Quant Biol*. 2008; 73:427–37. DOI: 10.1101/sqb.2008.73.047 [PubMed: 19150964]
89. Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, Dalla-Favera R, Dang CV. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. *Proc Natl Acad Sci U S A*. 1997; 94(13):6658–63. [PubMed: 9192621]
90. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. *Clin Cancer Res*. 2009; 15(21):6479–83. DOI: 10.1158/1078-0432.CCR-09-0889 [PubMed: 19861459]
91. Kim JW, Gao P, Liu YC, Semenza GL, Dang CV. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. *Mol Cell Biol*. 2007; 27(21):7381–93. DOI: 10.1128/MCB.00440-07 [PubMed: 17785433]
92. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, Nissim I, Daikhin E, Yudkoff M, McMahon SB, Thompson CB. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. *Proc Natl Acad Sci U S A*. 2008; 105(48):18782–7. DOI: 10.1073/pnas.0810199105 [PubMed: 19033189]
93. Jacks T, Weinberg RA. The expanding role of cell cycle regulators. *Science*. 1998; 280(5366):1035–6. [PubMed: 9616080]

94. Privat M, Radosevic-Robin N, Aubel C, Cayre A, Penault-Llorca F, Marceau G, Sapin V, Bignon YJ, Morvan D. BRCA1 induces major energetic metabolism reprogramming in breast cancer cells. *PLoS One*. 2014; 9(7):e102438.doi: 10.1371/journal.pone.0102438 [PubMed: 25010005]
95. Brunet J, Vazquez-Martin A, Colomer R, Grana-Suarez B, Martin-Castillo B, Menendez JA. BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancer. *Mol Carcinog*. 2008; 47(2):157–63. DOI: 10.1002/mc.20364 [PubMed: 17620310]
96. Li D, Bi FF, Chen NN, Cao JM, Sun WP, Zhou YM, Li CY, Yang Q. A novel crosstalk between BRCA1 and sirtuin 1 in ovarian cancer. *Sci Rep*. 2014; 4:6666.doi: 10.1038/srep06666 [PubMed: 25323003]
97. Pruthi S, Gostout BS, Lindor NM. Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer. *Mayo Clin Proc*. 2010; 85(12):1111–20. DOI: 10.4065/mcp.2010.0414 [PubMed: 21123638]
98. Xiang T, Ohashi A, Huang Y, Pandita TK, Ludwig T, Powell SN, Yang Q. Negative Regulation of AKT Activation by BRCA1. *Cancer Res*. 2008; 68(24):10040–4. DOI: 10.1158/0008-5472.CAN-08-3009 [PubMed: 19074868]
99. Kang HJ, Kim HJ, Rih JK, Mattson TL, Kim KW, Cho CH, Isaacs JS, Bae I. BRCA1 plays a role in the hypoxic response by regulating HIF-1alpha stability and by modulating vascular endothelial growth factor expression. *J Biol Chem*. 2006; 281(19):13047–56. DOI: 10.1074/jbc.M513033200 [PubMed: 16543242]
100. Martinez-Calatrava MJ, Gonzalez-Sanchez JL, Martinez-Larrad MT, Perez-Barba M, Serrano-Rios M. Common haplotypes of the C-reactive protein gene and circulating leptin levels influence the interindividual variability in serum C-reactive protein levels. The Segovia study. *Thromb Haemost*. 2007; 98(5):1088–95. [PubMed: 18000615]
101. Moreau K, Dizin E, Ray H, Luquain C, Lefai E, Foufelle F, Billaud M, Lenoir GM, Venezia ND. BRCA1 affects lipid synthesis through its interaction with acetyl-CoA carboxylase. *J Biol Chem*. 2006; 281(6):3172–81. DOI: 10.1074/jbc.M504652200 [PubMed: 16326698]
102. Lim SO, Li CW, Xia W, Lee HH, Chang SS, Shen J, Hsu JL, Raftery D, Djukovic D, Gu H, Chang WC, Wang HL, Chen ML, Huo L, Chen CH, Wu Y, Sahin A, Hanash SM, Hortobagyi GN, Hung MC. EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape. *Cancer Res*. 2016; 76(5):1284–96. DOI: 10.1158/0008-5472.CAN-15-2478 [PubMed: 26759242]
103. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. *Oncogene*. 2009; 28(Suppl 1):S24–31. DOI: 10.1038/onc.2009.198 [PubMed: 19680293]
104. Romano D, Maccario H, Doherty C, Quinn NP, Kolch W, Matallanas D. The differential effects of wild-type and mutated K-Ras on MST2 signaling are determined by K-Ras activation kinetics. *Mol Cell Biol*. 2013; 33(9):1859–68. DOI: 10.1128/MCB.01414-12 [PubMed: 23459937]
105. Castellano E, Downward J. Role of RAS in the regulation of PI 3-kinase. *Curr Top Microbiol Immunol*. 2010; 346:143–69. DOI: 10.1007/82_2010_56 [PubMed: 20563706]
106. Regad T. Targeting RTK Signaling Pathways in Cancer. *Cancers (Basel)*. 2015; 7(3):1758–84. DOI: 10.3390/cancers7030860 [PubMed: 26404379]
107. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. *Nat Rev Drug Discov*. 2009; 8(8):627–44. DOI: 10.1038/nrd2926 [PubMed: 19644473]
108. Barthel A, Okino ST, Liao J, Nakatani K, Li J, Whitlock JP Jr, Roth RA. Regulation of GLUT1 gene transcription by the serine/threonine kinase Akt1. *J Biol Chem*. 1999; 274(29):20281–6. [PubMed: 10400647]
109. Deprez J, Vertommen D, Alessi DR, Hue L, Rider MH. Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein kinase B and other protein kinases of the insulin signaling cascades. *J Biol Chem*. 1997; 272(28):17269–75. [PubMed: 9211863]
110. Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. *Genes Dev*. 2001; 15(11):1406–18. DOI: 10.1101/gad.889901 [PubMed: 11390360]

111. Berwick DC, Hers I, Heesom KJ, Moule SK, Tavaré JM. The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes. *J Biol Chem.* 2002; 277(37):33895–900. DOI: 10.1074/jbc.M204681200 [PubMed: 12107176]
112. Yang YA, Han WF, Morin PJ, Chrest FJ, Pizer ES. Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. *Exp Cell Res.* 2002; 279(1):80–90. [PubMed: 12213216]
113. Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. *Cell Death Differ.* 2008; 15(4):678–85. DOI: 10.1038/cdd.2008.21 [PubMed: 18259193]
114. Hirschhaeuser F, Sattler UG, Mueller-Klieser W. Lactate: a metabolic key player in cancer. *Cancer Res.* 2011; 71(22):6921–5. DOI: 10.1158/0008-5472.CAN-11-1457 [PubMed: 22084445]
115. Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. *J Clin Invest.* 2013; 123(9):3664–71. DOI: 10.1172/JCI67230 [PubMed: 23999440]
116. Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. *Mol Cell Biol.* 2003; 23(24):9361–74. [PubMed: 14645546]
117. Hayashi M, Sakata M, Takeda T, Yamamoto T, Okamoto Y, Sawada K, Kimura A, Minekawa R, Tahara M, Tasaka K, Murata Y. Induction of glucose transporter 1 expression through hypoxia-inducible factor 1alpha under hypoxic conditions in trophoblast-derived cells. *J Endocrinol.* 2004; 183(1):145–54. DOI: 10.1677/joe.1.05599 [PubMed: 15525582]
118. Liu Y, Li YM, Tian RF, Liu WP, Fei Z, Long QF, Wang XA, Zhang X. The expression and significance of HIF-1alpha and GLUT-3 in glioma. *Brain Res.* 2009; 1304:149–54. DOI: 10.1016/j.brainres.2009.09.083 [PubMed: 19782666]
119. Obach M, Navarro-Sabate A, Caro J, Kong X, Duran J, Gomez M, Perales JC, Ventura F, Rosa JL, Bartrons R. 6-Phosphofructo-2-kinase (pfkfb3) gene promoter contains hypoxia-inducible factor-1 binding sites necessary for transactivation in response to hypoxia. *J Biol Chem.* 2004; 279(51):53562–70. DOI: 10.1074/jbc.M406096200 [PubMed: 15466858]
120. Kress S, Stein A, Maurer P, Weber B, Reichert J, Buchmann A, Huppert P, Schwarz M. Expression of hypoxia-inducible genes in tumor cells. *J Cancer Res Clin Oncol.* 1998; 124(6):315–20. [PubMed: 9692838]
121. Ullah MS, Davies AJ, Halestrap AP. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. *J Biol Chem.* 2006; 281(14):9030–7. DOI: 10.1074/jbc.M511397200 [PubMed: 16452478]
122. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. *Cell Metab.* 2006; 3(3):177–85. DOI: 10.1016/j.cmet.2006.02.002 [PubMed: 16517405]
123. Lum JJ, Bui T, Gruber M, Gordan JD, DeBerardinis RJ, Covello KL, Simon MC, Thompson CB. The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. *Genes Dev.* 2007; 21(9):1037–49. DOI: 10.1101/gad.1529107 [PubMed: 17437992]
124. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. *Nature.* 1999; 399(6733):271–5. DOI: 10.1038/20459 [PubMed: 10353251]
125. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. *Cancer Res.* 2000; 60(6):1541–5. [PubMed: 10749120]
126. Kim Y, Nam HJ, Lee J, Park do Y, Kim C, Yu YS, Kim D, Park SW, Bhin J, Hwang D, Lee H, Koh GY, Baek SH. Methylation-dependent regulation of HIF-1alpha stability restricts retinal and tumour angiogenesis. *Nat Commun.* 2016; 7:10347.doi: 10.1038/ncomms10347 [PubMed: 26757928]
127. Yan Q, Chen P, Wang S, Liu N, Zhao P, Gu A. Association between HIF-1alpha C1772T/G1790A polymorphisms and cancer susceptibility: an updated systematic review and meta-analysis based

- on 40 case-control studies. *BMC Cancer*. 2014; 14:950.doi: 10.1186/1471-2407-14-950 [PubMed: 25496056]
128. Wang X, Liu Y, Ren H, Yuan Z, Li S, Sheng J, Zhao T, Chen Y, Liu F, Wang F, Huang H, Hao J. Polymorphisms in the hypoxia-inducible factor-1alpha gene confer susceptibility to pancreatic cancer. *Cancer Biol Ther*. 2011; 12(5):383–7. [PubMed: 21709439]
129. Neuhausen SL. Ethnic differences in cancer risk resulting from genetic variation. *Cancer*. 1999; 86(11 Suppl):2575–82. [PubMed: 10630184]
130. Hanna MC, Go C, Roden C, Jones RT, Pochanard P, Javed AY, Javed A, Mondal C, Palescandolo E, Van Hummelen P, Hatton C, Bass AJ, Chun SM, Na DC, Kim TI, Jang SJ, Osarogiagbon RU, Hahn WC, Meyerson M, Garraway LA, MacConaill LE. Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequency. *PLoS One*. 2013; 8(9):e74950.doi: 10.1371/journal.pone.0074950 [PubMed: 24066160]
131. Li CI, Malone KE, Daling JR. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. *Cancer Epidemiol Biomarkers Prev*. 2002; 11(7):601–7. [PubMed: 12101106]
132. de Bruin MA, Kwong A, Goldstein BA, Lipson JA, Ikeda DM, McPherson L, Sharma B, Kardashian A, Schackmann E, Kingham KE, Mills MA, West DW, Ford JM, Kurian AW. Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations. *Fam Cancer*. 2012; 11(3):429–39. DOI: 10.1007/s10689-012-9531-9 [PubMed: 22638769]
133. Fuhrman BJ, Schairer C, Gail MH, Boyd-Morin J, Xu X, Sue LY, Buys SS, Isaacs C, Keefer LK, Veenstra TD, Berg CD, Hoover RN, Ziegler RG. Estrogen metabolism and risk of breast cancer in postmenopausal women. *J Natl Cancer Inst*. 2012; 104(4):326–39. DOI: 10.1093/jnci/djr531 [PubMed: 22232133]
134. Quan L, Hong CC, Zirpoli G, Roberts MR, Khoury T, Sucheston-Campbell LE, Bovbjerg DH, Jandorf L, Pawlish K, Ciupak G, Davis W, Bandera EV, Ambrosone CB, Yao S. Variants of estrogen-related genes and breast cancer risk in European and African American women. *Endocr Relat Cancer*. 2014; 21(6):853–64. DOI: 10.1530/ERC-14-0250 [PubMed: 25228414]
135. Steuer CE, Behera M, Berry L, Kim S, Rossi M, Sica G, Owonikoko TK, Johnson BE, Kris MG, Bunn PA, Khuri FR, Garon EB, Ramalingam SS. Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium. *Cancer*. 2016; 122(5):766–72. DOI: 10.1002/cncr.29812 [PubMed: 26695526]
136. Kohno T, Kunitoh H, Suzuki K, Yamamoto S, Kuchiba A, Matsuno Y, Yanagitani N, Yokota J. Association of KRAS polymorphisms with risk for lung adenocarcinoma accompanied by atypical adenomatous hyperplasias. *Carcinogenesis*. 2008; 29(5):957–63. DOI: 10.1093/carcin/bgn048 [PubMed: 18299280]
137. Hunt JD, Strimas A, Martin JE, Eyer M, Haddican M, Luckett BG, Ruiz B, Axelrad TW, Backes WL, Fontham ET. Differences in KRAS mutation spectrum in lung cancer cases between African Americans and Caucasians after occupational or environmental exposure to known carcinogens. *Cancer Epidemiol Biomarkers Prev*. 2002; 11(11):1405–12. [PubMed: 12433719]
138. Pernick NL, Sarkar FH, Philip PA, Arlauskas P, Shields AF, Vaitkevicius VK, Dugan MC, Adsay NV. Clinicopathologic analysis of pancreatic adenocarcinoma in African Americans and Caucasians. *Pancreas*. 2003; 26(1):28–32. [PubMed: 12499914]
139. Kang M, Shen XJ, Kim S, Araujo-Perez F, Galanko JA, Martin CF, Sandler RS, Keku TO. Somatic gene mutations in African Americans may predict worse outcomes in colorectal cancer. *Cancer Biomark*. 2013; 13(5):359–66. DOI: 10.3233/CBM-130366 [PubMed: 24440976]
140. Yuan F, Shi M, Ji J, Shi H, Zhou C, Yu Y, Liu B, Zhu Z, Zhang J. KRAS and DAXX/ATRX gene mutations are correlated with the clinicopathological features, advanced diseases, and poor prognosis in Chinese patients with pancreatic neuroendocrine tumors. *Int J Biol Sci*. 2014; 10(9):957–65. DOI: 10.7150/ijbs.9773 [PubMed: 25210493]
141. Krishnaswamy S, Kanteti R, Duke-Cohan JS, Loganathan S, Liu W, Ma PC, Sattler M, Singleton PA, Ramnath N, Innocenti F, Nicolae DL, Ouyang Z, Liang J, Minna J, Kozloff MF, Ferguson MK, Natarajan V, Wang YC, Garcia JG, Vokes EE, Salgia R. Ethnic differences and functional analysis of MET mutations in lung cancer. *Clin Cancer Res*. 2009; 15(18):5714–23. DOI: 10.1158/1078-0432.CCR-09-0070 [PubMed: 19723643]

142. Bauml J, Mick R, Zhang Y, Watt CD, Vachani A, Aggarwal C, Evans T, Langer C. Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist? *Lung Cancer*. 2013; 81(3):347–53. DOI: 10.1016/j.lungcan.2013.05.011 [PubMed: 23806795]
143. Leidner RS, Fu P, Clifford B, Hamdan A, Jin C, Eisenberg R, Boggon TJ, Skokan M, Franklin WA, Cappuzzo F, Hirsch FR, Varella-Garcia M, Halmos B. Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. *J Clin Oncol*. 2009; 27(33):5620–6. DOI: 10.1200/JCO.2009.23.1431 [PubMed: 19786660]
144. Zhang W, McQuitty EB, Olsen R, Fan H, Hendrickson H, Tio FO, Newton K, Cagle PT, Jagirdar J. EGFR mutations in US Hispanic versus non-Hispanic white patients with lung adenocarcinoma. *Arch Pathol Lab Med*. 2014; 138(4):543–5. DOI: 10.5858/arpa.2013-0311-OA [PubMed: 23937608]
145. Buttitta F, Barassi F, Fresu G, Felicioni L, Chella A, Paolizzi D, Lattanzio G, Salvatore S, Camplese PP, Rosini S, Iarussi T, Mucilli F, Sacco R, Mezzetti A, Marchetti A. Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. *Int J Cancer*. 2006; 119(11):2586–91. DOI: 10.1002/ijc.22143 [PubMed: 16988931]
146. Faubert B, Vincent EE, Griss T, Samborska B, Izreig S, Svensson RU, Mamer OA, Avizonis D, Shackelford DB, Shaw RJ, Jones RG. Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1 α . *Proc Natl Acad Sci U S A*. 2014; 111(7):2554–9. DOI: 10.1073/pnas.1312570111 [PubMed: 24550282]
147. Gao B, Sun Y, Zhang J, Ren Y, Fang R, Han X, Shen L, Liu XY, Pao W, Chen H, Ji H. Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas. *J Thorac Oncol*. 2010; 5(8):1130–5. DOI: 10.1097/JTO.0b013e3181e05016 [PubMed: 20559149]
148. Blaszyk H, Vaughn CB, Hartmann A, McGovern RM, Schroeder JJ, Cunningham J, Schaid D, Sommer SS, Kovach JS. Novel pattern of p53 gene mutations in an American black cohort with high mortality from breast cancer. *Lancet*. 1994; 343(8907):1195–7. [PubMed: 7909871]
149. Hill KA, Sommer SS. p53 as a mutagen test in breast cancer. *Environ Mol Mutagen*. 2002; 39(2-3):216–27. [PubMed: 11921192]
150. Dong G, He X, Chen Y, Cao H, Wang J, Liu X, Wang S, Wan S, Xing J. Genetic variations in genes of metabolic enzymes predict postoperative prognosis of patients with colorectal cancer. *Mol Cancer*. 2015; 14:171.doi: 10.1186/s12943-015-0442-x [PubMed: 26377099]
151. Patel YM, Park SL, Carmella SG, Paiano V, Olvera N, Stram DO, Haiman CA, Le Marchand L, Hecht SS. Metabolites of the Polycyclic Aromatic Hydrocarbon Phenanthrene in the Urine of Cigarette Smokers from Five Ethnic Groups with Differing Risks for Lung Cancer. *PLoS One*. 2016; 11(6):e0156203.doi: 10.1371/journal.pone.0156203 [PubMed: 27275760]
152. Murphy SE, Park SS, Thompson EF, Wilkens LR, Patel Y, Stram DO, Le Marchand L. Nicotine N-glucuronidation relative to N-oxidation and C-oxidation and UGT2B10 genotype in five ethnic/racial groups. *Carcinogenesis*. 2014; 35(11):2526–33. DOI: 10.1093/carcin/bgu191 [PubMed: 25233931]
153. Budhu A, Terunuma A, Zhang G, Hussain SP, Ambs S, Wang XW. Metabolic profiles are principally different between cancers of the liver, pancreas and breast. *Int J Biol Sci*. 2014; 10(9):966–72. DOI: 10.7150/ijbs.9810 [PubMed: 25210494]
154. Chen L, Chen H, Li Y, Li L, Qiu Y, Ren J. Endocannabinoid and ceramide levels are altered in patients with colorectal cancer. *Oncol Rep*. 2015; 34(1):447–54. DOI: 10.3892/or.2015.3973 [PubMed: 25975960]
155. Mishra P, Ambs S. Metabolic Signatures of Human Breast Cancer. *Mol Cell Oncol*. 2015; 2(3)doi: 10.4161/23723556.2014.992217
156. Rocha CM, Carrola J, Barros AS, Gil AM, Goodfellow BJ, Carreira IM, Bernardo J, Gomes A, Sousa V, Carvalho L, Duarte IF. Metabolic signatures of lung cancer in biofluids: NMR-based metabolomics of blood plasma. *J Proteome Res*. 2011; 10(9):4314–24. DOI: 10.1021/pr200550p [PubMed: 21744875]
157. Bathe OF, Shaykhtudinov R, Kopciuk K, Weljie AM, McKay A, Sutherland FR, Dixon E, Dunse N, Sotiropoulos D, Vogel HJ. Feasibility of identifying pancreatic cancer based on serum

metabolomics. *Cancer Epidemiol Biomarkers Prev.* 2011; 20(1):140–7. DOI: 10.1158/1055-9965.EPI-10-0712 [PubMed: 21098649]

158. Di Gangi IM, Mazza T, Fontana A, Copetti M, Fusilli C, Ippolito A, Mattivi F, Latiano A, Andriulli A, Vrhovsek U, Pazienza V. Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites. *Oncotarget.* 2016; 7(5): 5815–29. DOI: 10.18632/oncotarget.6808 [PubMed: 26735340]
159. Ritchie SA, Akita H, Takemasa I, Eguchi H, Pastural E, Nagano H, Monden M, Doki Y, Mori M, Jin W, Sajobi TT, Jayasinghe D, Chitou B, Yamazaki Y, White T, Goodenowe DB. Metabolic system alterations in pancreatic cancer patient serum: potential for early detection. *BMC Cancer.* 2013; 13:416.doi: 10.1186/1471-2407-13-416 [PubMed: 24024929]
160. Daemen A, Peterson D, Sahu N, McCord R, Du X, Liu B, Kowanetz K, Hong R, Moffat J, Gao M, Boudreau A, Mroue R, Corson L, O'Brien T, Qing J, Sampath D, Merchant M, Yauch R, Manning G, Settleman J, Hatzivassiliou G, Evangelista M. Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors. *Proc Natl Acad Sci U S A.* 2015; 112(32):E4410–7. DOI: 10.1073/pnas.1501605112 [PubMed: 26216984]
161. Gao L, Wen Z, Wu C, Wen T, Ong CN. Metabolic profiling of plasma from benign and malignant pulmonary nodules patients using mass spectrometry-based metabolomics. *Metabolites.* 2013; 3(3):539–51. DOI: 10.3390/metabo3030539 [PubMed: 24958138]
162. Rocha CM, Barros AS, Goodfellow BJ, Carreira IM, Gomes A, Sousa V, Bernardo J, Carvalho L, Gil AM, Duarte IF. NMR metabolomics of human lung tumours reveals distinct metabolic signatures for adenocarcinoma and squamous cell carcinoma. *Carcinogenesis.* 2015; 36(1):68–75. DOI: 10.1093/carcin/bgu226 [PubMed: 25368033]
163. Marien E, Meister M, Muley T, Fieuws S, Bordel S, Derua R, Spraggins J, Van de Plas R, Dehairs J, Wouters J, Bagadi M, Dienemann H, Thomas M, Schnabel PA, Caprioli RM, Waelkens E, Swinnen JV. Non-small cell lung cancer is characterized by dramatic changes in phospholipid profiles. *Int J Cancer.* 2015; 137(7):1539–48. DOI: 10.1002/ijc.29517 [PubMed: 25784292]
164. Farshidfar F, Weljie AM, Kopciuk K, Buie WD, Maclean A, Dixon E, Sutherland FR, Molckovsky A, Vogel HJ, Bathe OF. Serum metabolomic profile as a means to distinguish stage of colorectal cancer. *Genome Med.* 2012; 4(5):42.doi: 10.1186/gm341 [PubMed: 22583555]
165. Schnitt SJ. Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. *Mod Pathol.* 2010; 23(Suppl 2):S60–4. DOI: 10.1038/modpathol.2010.33 [PubMed: 20436504]
166. Cao MD, Lamichhane S, Lundgren S, Bofin A, Fjosne H, Giskeodegard GF, Bathen TF. Metabolic characterization of triple negative breast cancer. *BMC Cancer.* 2014; 14:941.doi: 10.1186/1471-2407-14-941 [PubMed: 25495193]
167. Budczies J, Brockmoller SF, Muller BM, Barupal DK, Richter-Ehrenstein C, Kleine-Tebbe A, Griffin JL, Oresic M, Dietel M, Denkert C, Fiehn O. Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism. *J Proteomics.* 2013; 94:279–88. DOI: 10.1016/j.jpro.2013.10.002 [PubMed: 24125731]
168. Sturtz LA, Melley J, Mamula K, Shriver CD, Ellsworth RE. Outcome disparities in African American women with triple negative breast cancer: a comparison of epidemiological and molecular factors between African American and Caucasian women with triple negative breast cancer. *BMC Cancer.* 2014; 14:62.doi: 10.1186/1471-2407-14-62 [PubMed: 24495414]
169. Brunelli L, Caiola E, Marabese M, Broggin M, Pastorelli R. Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells. *Oncotarget.* 2014; 5(13):4722–31. DOI: 10.18632/oncotarget.1958 [PubMed: 24952473]
170. Gieger C, Geistlinger L, Altmaier E, Hrab de Angelis M, Kronenberg F, Meitinger T, Mewes HW, Wichmann HE, Weinberger KM, Adamski J, Illig T, Suhre K. Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. *PLoS Genet.* 2008; 4(11):e1000282.doi: 10.1371/journal.pgen.1000282 [PubMed: 19043545]
171. Shen J, Yan L, Liu S, Ambrosone CB, Zhao H. Plasma metabolomic profiles in breast cancer patients and healthy controls: by race and tumor receptor subtypes. *Transl Oncol.* 2013; 6(6): 757–65. [PubMed: 24466379]

172. Jing L, Su L, Ring BZ. Ethnic background and genetic variation in the evaluation of cancer risk: a systematic review. *PLoS One*. 2014; 9(6):e97522.doi: 10.1371/journal.pone.0097522 [PubMed: 24901479]
173. Ollberding NJ, Nomura AM, Wilkens LR, Henderson BE, Kolonel LN. Racial/ethnic differences in colorectal cancer risk: the multiethnic cohort study. *Int J Cancer*. 2011; 129(8):1899–906. DOI: 10.1002/ijc.25822 [PubMed: 21128280]
174. Taioli E, Benhamou S, Bouchardy C, Cascorbi I, Cajas-Salazar N, Dally H, Fong KM, Larsen JE, Le Marchand L, London SJ, Risch A, Spitz MR, Stucker I, Weinschenker B, Wu X, Yang P. Myeloperoxidase G-463A polymorphism and lung cancer: a HuGE genetic susceptibility to environmental carcinogens pooled analysis. *Genet Med*. 2007; 9(2):67–73. doi:10.1097/GIM.0b013e31803068b1. [PubMed: 17304047]
175. Dally H, Gassner K, Jager B, Schmezer P, Spiegelhalder B, Edler L, Drings P, Dienemann H, Schulz V, Kayser K, Bartsch H, Risch A. Myeloperoxidase (MPO) genotype and lung cancer histologic types: the MPO -463 A allele is associated with reduced risk for small cell lung cancer in smokers. *Int J Cancer*. 2002; 102(5):530–5. DOI: 10.1002/ijc.10756 [PubMed: 12432558]
176. Wright JL, Reis IM, Zhao W, Panoff JE, Takita C, Sujoy V, Gomez CR, Jorda M, Franceschi D, Hurley J. Racial disparity in estrogen receptor positive breast cancer patients receiving trimodality therapy. *Breast*. 2012; 21(3):276–83. DOI: 10.1016/j.breast.2011.11.003 [PubMed: 22178596]
177. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science*. 2004; 304(5676):1497–500. DOI: 10.1126/science.1099314 [PubMed: 15118125]
178. Wu F, Zhang J, Hu N, Wang H, Xu T, Liu Y, Zheng Y. Effect of hENT1 polymorphism G-706C on clinical outcomes of gemcitabine-containing chemotherapy for Chinese non-small-cell lung cancer patients. *Cancer Epidemiol*. 2014; 38(6):728–32. DOI: 10.1016/j.canep.2014.08.008 [PubMed: 25246379]
179. Romero-Lorca A, Novillo A, Gaibar M, Bandres F, Fernandez-Santander A. Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients. *PLoS One*. 2015; 10(7):e0132269.doi: 10.1371/journal.pone.0132269 [PubMed: 26176234]
180. Efferth T, Volm M. Pharmacogenetics for individualized cancer chemotherapy. *Pharmacol Ther*. 2005; 107(2):155–76. DOI: 10.1016/j.pharmthera.2005.02.005 [PubMed: 15890408]
181. Lee W, Lockhart AC, Kim RB, Rothenberg ML. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. *Oncologist*. 2005; 10(2):104–11. DOI: 10.1634/theoncologist.10-2-104 [PubMed: 15709212]
182. Pommier AJ, Farren M, Patel B, Wappett M, Michopoulos F, Smith NR, Kendrew J, Frith J, Huby R, Eberlein C, Campbell H, Womack C, Smith PD, Robertson J, Morgan S, Critchlow SE, Barry ST. Leptin, BMI, and a Metabolic Gene Expression Signature Associated with Clinical Outcome to VEGF Inhibition in Colorectal Cancer. *Cell Metab*. 2016; 23(1):77–93. DOI: 10.1016/j.cmet.2015.10.015 [PubMed: 26626460]
183. Yoon HH, Shi Q, Alberts SR, Goldberg RM, Thibodeau SN, Sargent DJ, Sinicrope FA, O. Alliance for Clinical Trials in. Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients. *J Natl Cancer Inst*. 2015; 107(10)doi: 10.1093/jnci/djv186
184. Paik PK, Arcila ME, Fara M, Sima CS, Miller VA, Kris MG, Ladanyi M, Riely GJ. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. *J Clin Oncol*. 2011; 29(15):2046–51. DOI: 10.1200/JCO.2010.33.1280 [PubMed: 21483012]
185. Li Z, Liu XW, Chi ZC, Sun BS, Cheng Y, Cheng LW. Detection of K-ras Mutations in Predicting Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitor in Patients with Metastatic Colorectal Cancer. *PLoS One*. 2015; 10(5):e0101019.doi: 10.1371/journal.pone.0101019 [PubMed: 25950441]
186. Zhou W, Christiani DC. East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians. *Chin J Cancer*. 2011; 30(5):287–92. [PubMed: 21527061]

187. Reinersman JM, Johnson ML, Riely GJ, Chitale DA, Nicastrì AD, Soff GA, Schwartz AG, Sima CS, Ayalew G, Lau C, Zakowski MF, Rusch VW, Ladanyi M, Kris MG. Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. *J Thorac Oncol*. 2011; 6(1): 28–31. DOI: 10.1097/JTO.0b013e3181fb4fe2 [PubMed: 21107288]
188. Linardou H, Dahabreh IJ, Kanakoupiti D, Siannis F, Bafaloukos D, Kosmidis P, Papadimitriou CA, Murray S. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. *Lancet Oncol*. 2008; 9(10):962–72. DOI: 10.1016/S1470-20450870206-7 [PubMed: 18804418]
189. Mao C, Qiu LX, Liao RY, Du FB, Ding H, Yang WC, Li J, Chen Q. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. *Lung Cancer*. 2010; 69(3):272–8. DOI: 10.1016/j.lungcan.2009.11.020 [PubMed: 20022659]
190. Terunuma A, Putluri N, Mishra P, Mathe EA, Dorsey TH, Yi M, Wallace TA, Issaq HJ, Zhou M, Killian JK, Stevenson HS, Karoly ED, Chan K, Samanta S, Prieto D, Hsu TY, Kurley SJ, Putluri V, Sonavane R, Edelman DC, Wulff J, Starks AM, Yang Y, Kittles RA, Yfantis HG, Lee DH, Ioffe OB, Schiff R, Stephens RM, Meltzer PS, Veenstra TD, Westbrook TF, Sreekumar A, Ambis S. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. *J Clin Invest*. 2014; 124(1):398–412. DOI: 10.1172/JCI71180 [PubMed: 24316975]
191. Tishkoff SA, Verrelli BC. Patterns of human genetic diversity: implications for human evolutionary history and disease. *Annu Rev Genomics Hum Genet*. 2003; 4:293–340. DOI: 10.1146/annurev.genom.4.070802.110226 [PubMed: 14527305]
192. Zahm SH, Fraumeni JF Jr. Racial, ethnic, and gender variations in cancer risk: considerations for future epidemiologic research. *Environ Health Perspect*. 1995; 103(Suppl 8):283–6. [PubMed: 8741799]

Figure 1. Racial disparity in incidence and mortality rates of cancer

The graph represents age-adjusted (a) percent incidence rates, and (b) percent mortality rates of lung, breast, colorectal and pancreatic cancers in different races in the United States from the year 2009-2013. The data is taken from Surveillance, Epidemiology, and End Results report released in 2016 by National Cancer Institute.

Figure 2. The mutational landscape of metabolic pathways in cancer

Mutations in key genes coding for enzymes regulating metabolic reprogramming in cancer cells are highlighted in red. Colored square boxes represent the presence of mutations in cancers of different origin (red = lung cancer; blue = breast cancer; yellow = colorectal cancer; pink = pancreatic cancer; and black = absence of mutation).

Figure 3. Racial disparity in the mutational profile of metabolic oncoregulators

Depiction of various metabolic interactions regulated by oncoregulatory genes in cancer.

Colored square boxes represent the presence of mutations in cancers of different origin (red = lung cancer, blue = breast cancer, yellow = colorectal cancer, pink = pancreatic cancer and black = absence of mutation). Red colored arrows indicate interactions regulated by metabolic oncoregulators. Small dots marked above the square box represent the cancer type in which race-specific genetic mutation frequency is reported (red = lung cancer, blue = breast cancer, yellow = colorectal cancer, pink = pancreatic cancer and black = absence of mutation).

Table 1
Racial disparity in oncomutations found in metabolic enzymes and regulators

Cancer	Population	No. of Subjects	Molecular Marker	Patient/Tumor Characteristics	References
Breast	Asian, Caucasian	50, 49	<i>BRCA1</i> & <i>BRCA2</i>	<i>BRCA1</i> mutations more in Caucasians & <i>BRCA2</i> more in Asian	(132)
Lung	African-Americans, Native Hawaiians, Whites, Latinos, Japanese Americans	331–709 from each ethnic group	<i>GSTT2</i>	Mutation in <i>GSTT2</i> correlated with PheT	(151)
Colorectal	Asian, African-American, Caucasian	83, 149, 195	<i>BRAF</i>	Lower mutation frequency in Asians	(130)
Lung	African-American, Caucasian	513	<i>EGFR</i> & <i>KRAS</i>	Association of race with <i>EGFR</i> mutation in NSCLC	(142)
Lung	African-American, Caucasian	53, 102	<i>EGFR</i>	Caucasians had more activation mutations in NSCLC	(143)
Lung	Hispanic American, Non-Hispanic American	40, 43	<i>EGFR</i>	Similar mutation rate in adenocarcinomas from both groups	(144)
Breast	European, African	1307(658 cases), 1365(621 cases)	Estrogen pathway	SNPs in <i>ESR1</i> gene associated with Europeans	(134)
Breast	Ashkenazic Jews, Icelandic	138, 662	<i>BRCA1</i> & <i>BRCA2</i>	Founder mutations	(129)
Colorectal	African-American, Caucasian	67, 237	<i>KRAS</i> , <i>BRAF</i> , <i>PIK3CA</i>	<i>KRAS</i> mutation more common in African-Americans	(139)
Lung	Caucasian	403	<i>HER2</i>	<i>HER2</i> mutation higher in female adenocarcinomas	(145)
Lung	Chinese	239	<i>LKB1</i> , <i>EGFR</i> , <i>KRAS</i>	<i>LKB1</i> mutation in 6.9%adenocarcinoma patients	(147)
Lung	African-American, Caucasian	116 lung tumors	<i>KRAS</i>	More serine mutations	(137)
Pancreatic	African-American, Caucasian	166, 244	<i>KRAS</i>	African-Americans had high rates of <i>KRAS</i> mutations to Valine	(138)
Pancreatic	Chinese	37	<i>KRAS</i>	Mutation rates different than Caucasians	(140)
Lung	African-American, Native Hawaiian, Caucasian , Latino, Japanese American	364, 311, 437, 453, 674	<i>UGT2B10</i>	Nicotine metabolism associated with variant alleles	(152)
Lung	Caucasian, African-American, Asian, Latino	5838, 60, 48, 28	10 oncogenes	Difference in prevalence of oncogenic drivers	(135)
Lung	Asian, Caucasian, African-American	141, 76,66	<i>MET</i> , <i>EGFR</i> , <i>KRAS</i> , <i>TP53</i>	Germline <i>MET</i> mutations in East Asians	(141)
Colorectal	Chinese	697,256	TCA enzymes	TCA enzyme mutations associated with Chinese population	(150)
Breast & Lung	15 Populations	75	<i>TP53</i>	Higher frequency of all transition type mutations in African-Americans	(149)
Breast	African-American, Caucasian	47	<i>TP53</i>	Higher incidence of A:T→G:C	(148)
Breast	African-American, Caucasian	60	<i>Metabolites</i>	High level of fatty acids in plasma from TNBC patients	(171)
Colon	Asian, African-American, Caucasian	3305	<i>KRAS</i> , <i>BRAF</i>	Lower mutation rate in Asians	(183)